studi
biomark
variou
diseas
help
improv
manag
three
way
provid
better
understand
diseas
pathomechanismbi
improv
diagnosi
determin
prognosisbi
provid
basi
develop
therapeut
monitor
effect
therapeut
diseas
biomark
use
either
diseas
predict
treatment
one
sever
properti
includingspecif
select
associ
ill
populationheritabilityindepend
indic
presenc
diseas
regardless
presenc
absenc
clinic
phenotypecosegreg
diseas
within
familiespres
rel
affect
individu
higher
rate
gener
popul
biomark
fulfil
three
criteria
use
clinic
accur
repeat
measur
must
avail
clinician
reason
cost
short
turnaround
timesth
biomark
must
provid
inform
alreadi
avail
care
clinic
assessmentth
measur
level
aid
medic
decis
make
although
one
singl
biomark
fulfil
condit
multipl
relev
diseas
biomark
examin
concurr
increas
diagnost
specif
import
therapeut
area
current
focu
biomark
discoveri
cancer
metabol
disord
inflammatori
disord
diseas
nervou
system
cardiovascular
system
diseas
overlap
within
categori
mani
diseas
multipl
biomark
due
involv
differ
pathway
biomark
eg
inflamm
occur
sever
diseas
character
inflamm
inflamm
compon
mani
disord
discuss
accord
system
involv
major
disord
inflamm
involv
cardiovascular
nervou
system
diseas
diabet
rheumatoid
arthriti
character
inflamm
complement
system
activ
virtual
inflammatori
diseas
therefor
serv
fertil
sourc
biomark
inflamm
tradit
complement
activ
monitor
measur
serum
parent
molecul
substrat
enzymat
activ
howev
assay
known
limit
util
monitor
inflammatori
process
oxid
injuri
macromolecul
implic
wide
rang
patholog
condit
damag
mediat
via
free
radic
creat
rang
agent
eg
xenobiot
radiat
injuri
normal
metabol
activ
free
radic
damag
dna
lead
mutat
carcinogenesi
cell
death
form
free
radic
damag
dna
sensit
specif
indic
oxid
dna
damag
previous
difficult
detect
requir
purif
dna
howev
util
bind
protein
high
avid
specif
oxydna
test
biotrin
provid
simpl
conveni
sensit
fluoresc
method
detect
oxid
dna
protein
import
molecular
indic
oxidativenitros
damag
certain
whether
presenc
oxidativelynitros
modifi
protein
causal
role
simpli
reflect
secondari
effect
direct
identif
character
modifi
protein
given
diseas
deciph
potenti
role
play
rosrnsinduc
protein
modif
msbase
technolog
contribut
significantli
toward
better
understand
diseas
process
studi
oxidativenitros
modif
investig
redox
proteom
contribut
establish
relationship
patholog
hallmark
diseas
protein
structur
function
abnorm
msbase
technolog
use
discoveri
diagnost
biomark
oxidativenitros
stress
enabl
earli
detect
diseas
identif
character
oxidativelynitros
modifi
protein
human
diseas
start
hne
major
product
lipid
peroxid
process
consequ
free
radic
reaction
enzym
immunoassay
eia
major
urinari
metabolit
hne
ie
mercaptur
acid
dhnma
develop
valid
gueraud
et
al
eia
enabl
direct
measur
dhnma
rat
urin
good
sensit
precis
crossreact
low
differ
mercaptur
acid
except
one
hne
urinari
metabolit
good
correl
obtain
eia
liquid
lcm
quantit
analyz
urin
sampl
rat
differ
oxid
statu
due
treatment
either
brccl
trinitrobenzen
sulfon
acid
known
induc
hepat
lipid
peroxid
colon
inflamm
respect
consider
inform
avail
biomark
metabol
disord
use
biomark
well
establish
coverag
metabol
disord
beyond
scope
chapter
exampl
acut
intermitt
porphyria
liver
x
receptor
diabet
metabol
syndrom
discuss
section
acut
intermitt
porphyria
aip
metabol
diseas
caus
defici
hydroxymethylbilan
synthas
affect
hepat
heme
biosynthesi
clinic
manifest
abdomin
pain
neuroviscer
symptom
accompani
overproduct
heme
precursor
liver
frequent
remain
longlast
aip
patient
treatment
base
symptomat
relief
togeth
carbohydr
load
sever
attack
heme
therapi
acut
attack
heme
precursor
porphobilinogen
pbg
acid
ala
produc
high
amount
liver
found
high
concentr
plasma
urin
metabolit
repres
acutephas
reactant
confirm
ongo
attack
use
evalu
therapeut
measur
biochem
monitor
acut
attack
accur
reflect
plasma
pbg
plasma
ala
urinari
pbg
ala
sardh
et
al
aip
may
associ
alter
hepat
protein
known
either
increas
decreas
serum
accord
divers
patholog
condit
includ
malnutrit
inflamm
liver
diseas
serum
protein
within
normal
limit
patient
howev
insulinlik
growth
factor
decreas
aip
patient
transthyretin
prealbumin
found
significantli
decreas
delabi
et
al
use
transthyretin
propos
biomark
diseas
morbiditysever
clinic
followup
aip
patient
liver
x
receptor
lxr
nuclear
receptor
play
central
role
transcript
control
lipid
metabol
use
biomark
metabol
disord
lxr
function
nuclear
cholesterol
sensor
activ
respons
elev
intracellular
cholesterol
level
multipl
cell
type
activ
lxr
induc
express
array
gene
involv
cholesterol
absorpt
efflux
transport
excret
addit
function
lipid
metabol
lxr
also
found
modul
immun
inflammatori
respons
macrophag
synthet
lxr
agonist
promot
cholesterol
efflux
inhibit
inflamm
vivo
inhibit
develop
atherosclerosi
anim
model
abil
lxr
integr
metabol
inflammatori
signal
make
particularli
attract
target
intervent
human
metabol
diseas
lxr
agonist
prevent
develop
progress
atherosclerosi
inhibit
neointima
format
follow
angioplasti
arteri
wall
metabol
characterist
hyperglycemia
diabet
low
insulin
increas
free
fatti
acid
keton
serum
well
known
exhal
methyl
nitrat
shown
strongli
correl
specif
acut
spontan
hyperglycemia
type
diabet
mellitu
children
use
noninvas
biomark
hyperglycemia
novak
et
al
ga
analysi
perform
breath
sampl
via
ga
chromatographi
use
electron
captur
flame
ioniz
mass
select
detect
kinet
profil
exhal
methyl
nitrat
commonli
present
room
air
rang
part
per
trillion
strongli
statist
correl
plasma
glucos
healthi
subject
exhal
methyl
nitrat
concentr
slightli
greater
room
air
concentr
indic
small
net
output
ga
human
bodi
biochem
product
ga
postul
howev
result
studi
show
oxid
process
play
major
role
product
studi
variou
biomark
made
patient
diabet
mellitu
control
uncontrol
show
erythrocyt
glutathion
peroxidas
activ
glutathion
content
plasma
betacaroten
significantli
lower
diabet
patient
compar
normal
subject
signific
differ
patient
diseas
control
antioxid
enzym
superoxid
dismutas
sod
activ
significantli
higher
erythrocyt
diabet
patient
independ
presenc
microvascular
complic
howev
plasma
alphatocopheroltot
lipid
ratio
significantli
diminish
control
diabet
group
compar
uncontrol
diabet
group
lipid
peroxid
indic
measur
plasma
includ
malondialdehyd
lipid
hydroperoxid
lipoperoxid
significantli
elev
diabet
patient
regardless
presenc
complic
indic
oxid
damag
protein
type
diabet
associ
increas
vascular
complic
monocyt
pivot
cell
atherogenesi
type
diabet
subject
without
macrovascular
diseas
biomark
inflamm
creactiv
protein
plasmasolubl
cell
adhes
molecul
monocyt
nitrotyrosin
significantli
elev
compar
control
subject
devaraj
et
al
result
major
implic
understand
role
inflamm
vasculopathi
type
diabet
dyslipidemia
inflamm
may
promot
renal
diseas
via
mechan
vascular
endotheli
cell
dysfunct
type
ii
diabet
mellitu
crosssect
studi
men
diabet
mellitu
type
show
glomerular
filtrat
rate
gfr
mlminl
elev
triglycerid
lowdens
lipoprotein
apoprotein
b
fibrinogen
solubl
tumor
necrosi
factor
receptor
vascular
cell
adhes
lin
et
al
associ
creactiv
protein
gfr
conclud
sever
potenti
modifi
lipid
inflammatori
biomark
elev
set
moder
decreas
gfr
men
type
diabet
mellitu
may
link
renal
insuffici
increas
risk
cardiovascular
event
popul
diabes
term
use
syndrom
gradual
progress
obes
type
diabet
overlap
symptom
insulin
resist
hyperinsulinemia
hyperglycemia
dyslipidemia
ion
imbal
inflamm
busselton
studi
progress
australia
tri
identifi
biomark
blood
predict
onset
diabet
clinic
symptom
manifest
studi
conduct
proteom
intern
expertis
mass
spectrometri
collabor
fremantl
hospit
diabet
research
group
australia
person
diabet
chronic
hyperglycemia
assess
glycosyl
hemoglobin
level
associ
increas
risk
cardiovascular
diseas
combin
fast
plasma
glucos
glycosyl
hemoglobin
improv
accuraci
detect
patient
diabet
mellitu
type
combin
level
ogtt
enabl
precis
predict
progress
diabet
mellitu
type
subject
glucos
intoler
glycosyl
hemoglobin
valu
primari
target
glycem
control
american
diabet
associ
recommend
blood
test
measur
averag
level
glycemia
preced
month
perform
least
twice
year
patient
whose
treatment
goal
met
stabl
glycem
control
quarterli
patient
whose
treatment
chang
whose
goal
met
pancreat
cell
produc
proinsulin
split
cpeptid
insulin
releas
circul
cpeptid
bind
receptor
cell
surfac
activ
signal
transduct
pathway
result
stimul
na
katpas
endotheli
nitric
oxid
synthas
eno
enzym
reduc
activ
diabet
type
diabet
patient
proinsulin
produc
neither
insulin
cpeptid
form
lack
cprotein
thu
biomark
earli
peripher
neuropathi
diabet
pain
neuropathi
develop
structur
damag
nerv
replac
cpeptid
clinic
trial
creativ
peptid
stockholm
sweden
shown
improv
earli
sign
peripher
neuropathi
sensori
impair
concomit
improv
renal
dysfunct
normal
glomerular
filtrat
decreas
albumin
excret
reduc
diabetesinduc
structur
chang
decreas
mesangi
expans
cpeptid
replac
cpeptid
studi
use
surfac
plasmon
reson
spr
electrospray
mass
spectrometri
esim
show
proinsulin
found
influenc
interact
shafgat
et
al
technolog
use
measur
cprotein
biomark
insulin
resist
causal
role
type
diabet
serum
level
retinolbind
protein
secret
adipocyt
increas
insulinresist
state
level
serum
retinol
bind
adipocytederiv
signal
elev
insulinresist
mice
human
obes
type
diabet
normal
rosiglitazon
insulinsensit
drug
transgen
overexpress
human
inject
recombin
normal
mice
caus
insulin
resist
elev
serum
develop
frank
diabet
biomark
identifi
insulin
resist
associ
cardiovascular
risk
factor
subject
vari
clinic
present
graham
et
al
exercis
train
associ
reduct
serum
level
subject
insulin
resist
improv
adipocyt
protein
serum
level
invers
correl
find
provid
rational
antidiabet
therapi
aim
lower
serum
level
adiponectin
secret
adipocyt
account
approxim
total
plasma
protein
unlik
adipocyt
product
adiponectin
correl
decreas
free
fatti
acid
blood
concentr
reduc
bodi
mass
index
bodi
weight
well
establish
import
biomark
metabol
syndrom
complic
anim
cell
cultur
experi
also
support
claim
human
observ
role
metabol
syndrom
reproduc
result
human
genet
studi
divers
ethnic
origin
differ
investig
may
provid
evid
caus
role
pathogenesi
metabol
syndrom
insight
genet
constitut
metabol
syndrom
common
polymorph
promot
region
exon
intron
rare
nonsynonym
mutat
exon
human
adiponectin
gene
repeatedli
shown
mani
studi
mani
differ
ethnic
popul
associ
phenotyp
relat
bodi
weight
glucos
metabol
insulin
sensit
risk
type
diabet
mellitu
coronari
arteri
diseas
common
polymorph
rare
mutat
human
adiponectin
gene
demonstr
associ
differenti
express
adiponectin
plasma
protein
level
mrna
level
adipos
tissu
yang
chuang
variant
also
shown
influenc
insulin
sensit
interact
adiponectin
genotyp
influenc
plasma
adiponectin
level
howev
result
consist
three
genomewid
scan
loci
regul
plasma
adiponectin
concentr
suggest
explor
chromosom
requir
human
genet
studi
adiponectin
metabol
syndrom
strongli
suggest
adiponectin
one
caus
factor
pathogenesi
provid
signific
insight
genet
makeup
metabol
syndrom
extens
studi
may
acceler
discoveri
new
molecular
target
futur
therapeut
intervent
clinic
studi
confirm
treatment
thiazolidinedion
may
increas
adiponectin
concentr
patient
type
diabet
independ
improv
blood
glucos
control
parallel
treatment
insulinotrop
drug
find
suggest
adiponectin
may
diagnost
valu
use
especi
monitor
treatment
success
follow
transplant
major
organ
heart
kidney
liver
reject
graft
organ
import
problem
need
noninvas
test
monitor
patient
adjust
immunosuppress
drug
treatment
earli
detect
reject
need
discoveri
predict
biomark
patient
gene
express
signatur
studi
peripher
blood
mononuclear
cell
isol
patient
graft
versu
host
diseas
gvhd
well
immunosuppress
transplant
recipi
technolog
tcland
sa
provid
global
precis
pictur
tcell
mobil
combin
quantit
qualit
assess
tcr
gene
usag
origin
develop
analysi
monitor
tcell
immun
respons
compani
develop
specif
diagnost
biomark
well
proprietari
portfolio
therapeut
molecul
graft
patient
tcland
current
develop
therapeut
antibodi
select
inhibit
tcell
respons
direct
graft
molecul
new
antagonist
human
receptor
import
costimulatori
protein
express
cell
promis
preliminari
result
show
molecul
activ
treatment
graft
reject
accord
nih
consensu
develop
project
criteria
clinic
trial
chronic
gvhd
follow
applic
biomark
could
use
schultz
et
al
predict
respons
therapymeasur
diseas
activ
distinguish
irrevers
damag
continu
diseas
activitypredict
risk
develop
chronic
gvhddiagnos
chronic
gvhdpredict
prognosi
chronic
gvhdevalu
balanc
gvhd
graftversusleukemia
effect
graftversusleukemia
gvt
serv
surrog
end
point
therapeut
respons
date
valid
biomark
establish
chronic
gvhd
although
sever
candid
biomark
identifi
advanc
mani
highthroughput
omic
techniqu
genom
proteom
metabolom
effort
made
understand
potenti
mechan
specif
graft
injuri
develop
novel
biomark
acut
well
chronic
reject
sarwal
microarray
increasingli
use
identifi
specif
pattern
gene
express
predict
character
acut
chronic
reject
improv
understand
mechan
underli
organ
allograft
dysfunct
feasibl
develop
minim
invas
rapid
test
prognosi
diagnosi
person
manag
transplant
patient
surviv
renal
allograft
limit
chronic
allograft
deterior
result
process
difficult
detect
earli
stage
therapeut
intervent
would
effect
longterm
graft
loss
still
major
problem
renal
transplant
occurr
acut
reject
episod
impair
respons
patient
antireject
therapi
lead
advers
graft
outcom
short
term
long
term
current
clinic
featur
morpholog
assess
renal
biopsi
serv
basi
assess
risk
graft
failur
molecular
biomark
test
follow
purpos
monitor
acut
reject
identifi
steroidresist
reject
monitor
clinic
transplant
toler
predict
biomark
easili
access
specimen
blood
urin
might
improv
earli
diagnosi
graftdamag
process
help
identif
patient
particularli
high
risk
sustain
injuri
therebi
help
tailor
therapi
appropri
followup
screen
despit
larg
number
studi
predict
renal
allograft
failur
none
investig
candid
biomark
robustli
establish
widespread
clinic
use
abl
replac
biopsi
graft
assess
boenisch
chandrak
combin
molecular
analys
cellular
immunolog
assay
essenti
undisput
detect
reject
revers
reject
therapi
absenc
reject
longterm
graft
outcom
eikman
et
al
renal
biomark
panel
assay
life
technolog
corpor
noninvas
costeffect
research
tool
perform
kidney
function
posttransplant
studi
rapidli
easili
use
multiplex
technolog
bioassay
analysi
standard
immunoassay
format
offer
easeofus
sensit
rapid
reproduc
result
measur
level
cytokin
chemokin
receptor
level
urin
enabl
research
better
understand
immun
function
respons
assay
provid
research
altern
invas
expens
procedur
biopsi
obtain
kidney
tissu
sampl
enabl
research
posttransplant
kidney
function
quantif
mirna
primari
cultur
human
renal
epitheli
cell
hrec
shown
highli
express
hrec
stimul
result
decreas
express
anglicheau
et
al
studi
addit
suggest
cellular
basi
alter
intragraft
express
mirna
propos
mirna
express
pattern
may
serv
biomark
human
renal
allograft
statu
lung
transplant
patient
face
higher
death
rate
organ
recipi
die
within
year
recent
possibl
predict
transplant
failur
sign
chronic
reject
appear
usual
late
revers
aim
identifi
patient
risk
chronic
reject
clinic
manifest
protein
biomark
earli
sign
lung
transplant
reject
give
insight
physiolog
mechan
reject
may
provid
guid
manag
lung
transplant
patient
dose
antireject
drug
increas
biomark
appear
reduc
patient
without
earli
sign
reject
microarray
use
assess
gene
express
bronchoalveolar
lavag
cell
sampl
lung
transplant
recipi
without
acut
reject
simultan
lung
biopsi
land
et
al
studi
show
increas
express
acut
reject
gene
involv
inflamm
apoptosi
tcell
activ
prolifer
studi
murin
heterotop
tracheal
transplant
model
chronic
reject
demonstr
specif
pattern
gene
express
defin
time
point
transplant
allograft
wherea
gene
express
isograft
revert
back
nativ
trachea
within
week
transplant
studi
demonstr
potenti
power
microarray
identifi
biomark
acut
chronic
lung
reject
applic
new
genet
genom
proteom
technolog
infanc
microarraybas
studi
earli
stage
applic
lung
transplant
massiv
amount
data
gener
per
tissu
cell
sampl
spawn
outpour
invent
bioinformat
field
develop
method
turn
data
meaning
reproduc
clinic
infer
three
categori
drug
current
approv
sle
corticosteroid
antimalari
lowdos
aspirin
use
symptomat
relief
nonspecif
immunosuppress
recent
antibodi
dsdna
nuclear
antigen
sm
antigen
phospholipid
measur
complement
activ
use
togeth
clinic
score
indic
drug
efficaci
clinic
trial
clinic
score
satisfactori
consider
lag
period
initi
treatment
clinic
effect
two
potenti
biolog
drug
rituximab
drugapprov
agenc
unabl
assess
real
efficaci
reliabl
biomark
avail
lack
reliabl
specif
biomark
hamper
clinic
manag
system
lupu
erythematosu
sle
also
imped
develop
new
therapeut
agent
base
avail
data
sever
laboratori
marker
shown
promis
biomark
suscept
diagnosi
diseas
activ
despit
complex
mani
immunolog
pathway
involv
sle
biomark
emerg
character
patient
subgroup
predict
prognosi
indic
exacerb
remiss
sle
flare
serv
end
point
determin
dose
time
immunemodul
treatment
recent
sever
clinic
studi
test
new
therapi
directli
target
b
lymphocyt
flow
cytometri
circul
peripher
b
lymphocyt
use
defin
pathogen
subset
diseas
assess
therapeut
efficaci
biomark
sle
includ
fc
receptor
gene
diseas
suscept
complement
erythrocyt
diagnosi
diseas
activ
plasma
cell
diseas
activ
interferon
signatur
diseas
activ
antibodi
diseas
activ
organ
involv
promis
candid
biomark
need
valid
rigor
largescal
multicent
studi
still
urgent
need
better
biomark
monitor
diseas
activ
patient
sle
larg
databas
multicent
clinic
collabor
need
identifi
valid
biomark
sle
recogn
urgent
need
lupu
biomark
lupu
biomark
work
group
initi
unit
state
facilit
collabor
effort
aim
identifi
valid
biomark
sle
eu
biolupu
group
aim
appli
genom
proteom
construct
translat
databas
identif
biomark
clinic
util
develop
central
eu
databas
sle
thirtyf
particip
european
countri
involv
enterpris
involv
clinician
immunologist
geneticist
abnorm
level
activationderiv
fragment
complement
compon
deposit
surfac
erythrocyt
patient
sle
thu
reticulocyt
may
serv
biomark
diseas
activ
patient
sle
liu
et
al
also
report
upregul
patient
sle
might
candid
sle
biomark
synthetas
oa
known
previous
relat
sle
rediscov
involv
type
interferon
pathway
sle
sever
microarray
gene
express
studi
recent
show
pattern
oa
isoform
express
particularli
oasl
may
provid
use
inform
differenti
diseas
flare
certain
infect
sle
ye
et
al
adiponectin
adipocytederiv
cytokin
antiinflammatori
properti
plasma
adiponectin
level
increas
patient
renal
sle
compar
healthi
control
patient
nonren
sle
urin
patient
sle
kidney
involv
shown
previous
contain
immunoreact
adiponectin
reexamin
presenc
specif
adiponectin
isoform
nondenatur
gel
electrophoresi
song
et
al
high
molecular
weight
adiponectin
found
urin
patient
activ
lupu
nephriti
may
contribut
renal
inflamm
sle
new
proprietari
technolog
platform
sle
develop
univers
pittsburgh
arthriti
institut
pittsburgh
pa
base
cellbound
complement
activ
product
cbcap
superior
measur
serum
calano
et
al
assay
cbcap
bound
erythrocyt
platelet
white
blood
cell
perform
data
suggest
cbcap
may
serv
univers
biomark
diagnosi
diseas
activ
monitor
identif
diseas
subset
sle
identif
risk
catastroph
event
heart
attack
stroke
initi
studi
conduct
cohort
greater
sle
patient
compar
healthi
control
patient
diseas
data
demonstr
cbcap
diagnost
well
diseas
activ
monitor
properti
could
enhanc
even
replac
current
unsatisfactori
modal
pilot
data
also
gener
patient
hcv
infect
cardiovascular
diseas
transplant
complic
pregnanc
support
hypothesi
cbcap
may
serv
univers
biomark
inflamm
risk
sle
influenc
complex
genet
environment
contribut
allel
establish
suscept
gene
strong
evid
exist
addit
risk
loci
two
new
genet
loci
sle
promot
region
allel
associ
reduc
express
blk
increas
express
variant
region
identifi
confirm
replic
hom
et
al
epigenet
aberr
play
key
role
etiolog
sle
interact
dna
methyl
histon
modif
mirna
factor
pathogenesi
sle
zhao
et
al
advanc
knowledg
epigenet
sle
lead
discoveri
new
diagnost
prognost
biomark
well
novel
therapeut
target
strategi
scientist
univers
michigan
ann
arbor
mi
discov
level
methyl
certain
gene
close
associ
onset
sle
sensigen
licens
epigenet
biomark
develop
assay
lupu
base
attosens
technolog
combin
pcrm
quantit
methylationspecif
assay
determin
epigenet
chang
lupusassoci
biomark
rheumatoid
arthriti
ra
complex
inflammatori
diseas
numer
clinic
symptom
inadequ
defin
biomark
specif
diseas
tissu
prognost
biomark
signatur
identifi
character
without
prior
select
cluster
candid
gene
directli
clinic
strategi
redefin
biomark
complex
diseas
also
reassess
unappreci
diseas
mechan
ra
common
inflammatori
joint
disord
tool
avail
evalu
target
tissu
ra
proofofconcept
clinic
trial
synovi
biomark
yet
qualifi
surrog
end
point
regulatori
purpos
howev
evalu
intermedi
synovi
biomark
provid
uniqu
opportun
guid
develop
decis
make
target
tissu
measur
particularli
use
diseas
like
ra
patient
stratif
target
identif
integr
earli
clinic
trial
process
circul
cytokin
demonstr
correl
ra
diseas
activ
particip
directli
diseas
pathogenesi
presenc
tumor
necrosi
factor
tnf
serum
synovi
fluid
strong
indic
diseas
activ
ra
serv
biomark
target
therapi
neutral
antibodi
reliev
pain
improv
mobil
ra
patient
regulatori
cell
function
compromis
ra
indic
modul
regulatori
cell
therapi
may
mechan
diseas
amelior
etanercept
inhibitor
reduc
oxid
stress
biomark
level
dna
damag
lipid
peroxid
protein
glycosyl
patient
ra
kageyama
et
al
elev
level
serum
vegf
report
patient
ra
success
diseas
therapi
result
lower
level
vegf
serum
level
vegf
reduc
administr
antibodi
improv
patient
condit
omeract
solubl
biomark
group
success
formul
level
evid
scheme
studi
design
templat
provid
guidanc
conduct
valid
studi
set
solubl
biomark
propos
replac
measur
damag
end
point
ra
psoriat
arthriti
ankylos
spondyl
maksymowych
et
al
spondylarthr
spa
refer
group
chronic
autoimmun
arthrit
condit
includ
ankylos
spondyl
arthriti
associ
psoriasi
inflammatori
bowel
diseas
primarili
affect
peripher
joint
intern
allianc
research
synovi
tissu
analysi
present
ideal
vehicl
identifi
biomark
spa
hold
promis
facilit
progress
clinic
trial
dedic
improv
treatment
spa
kim
inman
studi
includ
patient
met
establish
criteria
spa
randomli
divid
three
group
two
group
treat
tumor
necrosi
factor
blocker
infliximab
etanercept
remain
patient
serv
control
studi
incept
culmin
patient
particip
thorough
assess
diseas
symptom
pain
interv
synovi
biopsi
perform
patient
needl
arthroscopi
knee
synovi
tissu
sampl
subject
extens
evalu
laboratori
test
includ
measur
abnorm
cell
growth
line
layer
vascular
growth
marker
cellular
infiltr
metalloproteinas
mmp
line
sublin
layer
treatment
group
patient
experienc
signific
improv
diseas
activ
pain
swollen
tender
joint
count
contrast
improv
control
group
among
synovi
featur
link
effect
research
found
chang
subset
synovi
macrophag
level
polymorphonuclear
cell
express
taken
togeth
find
indic
spa
patient
chang
diseas
activ
accompani
seri
distinct
measur
event
peripher
joint
synovi
featur
show
highli
differ
standard
respons
mean
spa
patient
receiv
effect
treatment
control
patient
valid
analys
independ
synovi
tissu
sampl
effect
treatment
correctli
predict
spa
patient
studi
need
confirm
valu
chang
observ
biomark
earli
time
point
across
differ
therapeut
regimen
combin
synovi
assess
predictor
respons
treatment
spa
immunopatholog
studi
suggest
featur
spondylarthropathi
distinct
support
promin
role
innat
immun
cell
consist
differenti
rheumatoid
arthriti
success
treatment
spondylarthropathi
synov
result
rapid
sustain
decreas
infiltr
macrophag
popul
neutrophil
decreas
express
mani
proinflammatori
mediat
consist
studi
rheumatoid
arthriti
signific
correl
effect
methotrex
infliximab
diseas
activ
sublin
macrophag
popul
report
bresnihan
observ
highlight
possibl
macrophag
popul
may
synovi
tissu
biomark
therapeut
intervent
spondylarthropathi
preliminari
studi
evalu
advanc
genom
proteom
methodolog
spondylarthropathi
surrog
marker
arthriti
activ
spondylarthropathi
could
profoundli
enhanc
screen
efficaci
optim
dose
rang
earlyphas
random
clinic
trial
osteoarthr
oa
pain
disord
joint
character
destruct
articular
cartilag
remodel
bone
molecular
level
loss
cartilag
proteoglycan
clearli
evid
rel
earli
stage
follow
eros
degrad
cartilag
compon
collagen
underli
bone
denud
cartilag
featur
common
ra
breakdown
cartilag
thought
mediat
releas
proteolyt
enzym
matrix
metalloproteinas
mmp
nitric
oxid
play
role
pathogenesi
oa
activ
synovi
cell
chondrocyt
oa
involv
differ
phase
earli
alter
biomechan
chronic
cytokinedriven
autodestruct
eg
modest
synovi
inflamm
oa
compar
ra
increas
mmp
metalloproteas
cytokin
overproduct
oa
cartilag
howev
alter
much
obviou
increas
tnf
tumor
necrosi
factor
ino
particularli
superfici
zone
multipl
effect
chondrocyt
includ
increas
mmp
apoptosi
proteoglycan
type
ii
collagen
product
oa
cartilag
appear
respons
alter
biomechan
accompani
local
increas
inflammatori
cytokin
particularli
also
differenti
express
extracellular
matrix
element
induc
catabol
phenotyp
chondrocyt
increas
apoptosi
antagon
decreas
product
oa
cartilag
explant
depend
demonstr
increas
suscept
oxid
injuri
oxid
stressinduc
apoptosi
cytokinestimul
chondrocyt
furthermor
induc
peroxynitrit
superoxid
anion
chondrocyt
exposur
chondrocyt
peroxynitrit
result
jun
ntermin
kinas
activ
transloc
nfkb
nucleu
regul
oa
cartilag
fibronectin
receptor
integrin
one
function
intraarticular
osteopontin
major
noncollagen
protein
bone
matrix
overexpress
oa
cartilag
act
innat
inhibitor
product
function
regul
interact
chondrocyt
differenti
express
protein
within
extracellular
matrix
diagnosi
usual
made
radiolog
studi
imag
involv
joint
arthroscopi
effort
made
develop
bloodbas
approach
identifi
oa
knee
gene
differenti
express
mild
knee
oa
control
sampl
identifi
microarray
analysi
blood
sampl
subsequ
realtim
rtpcr
verif
identifi
six
gene
significantli
downregul
mild
oa
heatshock
kda
protein
alpha
inhibitor
kappa
light
polypeptid
gene
enhanc
b
cell
kinas
complexassoci
protein
receptor
alpha
laminin
gamma
platelet
factor
also
known
chemokin
cxc
motif
ligand
tumor
necrosi
factor
alphainduc
protein
logist
regress
analysi
identifi
linear
combin
nine
gene
discriminatori
subject
mild
oa
control
six
gene
earli
growth
respons
alpha
glucosidas
ii
alpha
subunit
vmaf
musculoaponeurot
fibrosarcoma
oncogen
homolog
b
avian
linear
combin
blood
rna
biomark
thu
offer
substanti
improv
current
avail
diagnost
tool
mild
oa
bloodderiv
rna
biomark
may
signific
clinic
valu
diagnosi
earli
asymptomat
oa
knee
nation
institut
arthriti
musculoskelet
skin
diseas
start
recruit
osteoarthr
initi
partnership
nih
industri
fund
multisit
contract
creat
resourc
hasten
discoveri
biolog
marker
oa
men
women
age
older
risk
develop
oa
earli
diseas
elig
particip
initi
screen
four
center
around
unit
state
enrol
follow
adult
year
total
enrol
biolog
specimen
blood
urin
dna
imag
xray
mri
scan
clinic
data
collect
annual
region
analysi
femorotibi
ft
cartilag
loss
subsampl
osteoarthr
initi
progress
subcohort
show
rate
cartilag
loss
greater
central
subregion
entir
ft
cartilag
plate
wirth
et
al
final
result
may
avail
dual
xray
absorptiometri
dxa
scanner
wide
avail
offer
inexpens
precis
method
assess
bone
miner
densiti
mani
skelet
site
includ
lumbar
spine
proxim
femur
forearm
total
bodi
howev
qualiti
dxa
measur
vari
wide
clinic
clinic
among
geograph
region
addit
perform
scanner
impact
qualiti
measur
adjust
differ
calibr
manufactur
better
result
may
achiev
use
standard
equat
develop
scan
human
be
dxa
manufactur
adopt
formal
gener
standard
equat
develop
activ
intern
committe
standard
bone
measur
dxa
combin
molecular
biomark
bone
degrad
predict
fractur
risk
either
dxa
biomark
alon
quantit
ct
qct
mri
enabl
independ
measur
trabecular
cortic
bmd
well
bone
structur
deriv
measur
bone
strength
qct
mri
produc
tomograph
imag
bone
provid
imag
bone
geometri
use
measur
cortic
bone
dimens
type
collagen
molecul
bone
matrix
link
togeth
crosslink
molecul
includ
pyridinolin
pyd
deoxypyridinolin
dpd
region
n
ctelopeptid
dpd
differ
pyd
absenc
hydroxyl
residu
specif
bone
tissu
bone
resorpt
pyridinolin
releas
circul
excret
urin
free
form
link
c
ctx
n
ntx
telopeptid
differ
crosslink
form
measur
serum
urin
use
specif
immunoassay
target
use
biomark
could
optim
identif
highrisk
patient
process
drug
discoveri
monitor
efficaci
osteoporosi
treatment
clinic
set
roch
scientist
evalu
autom
multiplex
assay
biomark
bone
turnov
osteoporosi
serum
claudon
et
al
show
perform
characterist
similar
correspond
individu
measur
increas
analyt
sensit
low
rang
pinp
oc
assay
would
particularli
use
assess
bone
turnov
profil
clinic
studi
involv
larg
number
patient
sampl
volum
limit
procalcitonin
proct
precursor
peptid
hormon
calcitonin
ct
better
fulfil
requir
desir
biomark
compar
other
solid
scientif
basi
translat
ctmrna
proct
cleav
enzymat
smaller
peptid
final
yield
amino
acid
matur
ct
ct
precursor
peptid
includ
proct
found
serum
normal
person
microbi
infect
variou
form
inflamm
circul
level
sever
calcitonin
precursor
includ
proct
matur
ct
increas
sever
thousandfold
increas
especi
cours
correl
sever
condit
mortal
microbi
infect
induc
increas
calci
gene
express
releas
proct
parenchym
tissu
differenti
cell
type
throughout
bodi
commerci
avail
assay
base
timeresolv
amplifi
cryptat
emiss
trace
technolog
pct
brahm
hennigsdorf
germani
use
sheep
polyclon
anticalcitonin
antibodi
monoclon
antikatacalcin
antibodi
bind
calcitonin
katacalcin
sequenc
calcitonin
precursor
molecul
diagnost
accuraci
proct
shown
varieti
infect
eg
respiratori
tract
infect
mening
acut
infecti
endocard
pancreat
colorimetr
quick
bedsid
version
test
advantag
rapid
determin
circul
ctpr
level
min
assay
semiquantit
sensit
enough
detect
moder
elev
proct
level
proctbas
therapeut
strategi
safe
markedli
reduc
antibiot
usag
lower
respiratori
tract
infect
major
caus
sepsi
hormokin
mediat
immunoneutr
proct
might
offer
new
hope
effect
treatment
option
sepsi
evid
proct
provid
inform
therebi
question
current
use
gold
standard
diagnosi
clinic
relev
bacteri
infect
yet
proct
less
perfect
marker
proct
increas
noninfecti
condit
may
remain
low
infect
random
intervent
trial
conduct
patient
suspect
communityacquir
pneumonia
univers
hospit
basel
switzerland
assess
proct
guidanc
initi
durat
antibiot
therapi
christcrain
et
al
primari
end
point
antibiot
use
secondari
end
point
measur
clinic
laboratori
radiograph
outcom
proct
guidanc
reduc
total
antibiot
exposur
antibiot
prescript
admiss
antibiot
treatment
durat
compar
patient
treat
accord
guidelin
measur
proct
reduc
length
antibiot
treatment
averag
day
proct
appear
reliabl
measur
individu
tailor
earli
discontinu
antibiot
therapi
compar
routin
use
clinic
paramet
also
time
costeffect
took
less
min
detect
level
serum
procalcitonin
laboratori
result
routin
avail
within
hour
endotoxin
candid
diagnost
tool
infect
sever
year
howev
inconsist
increas
level
variat
sensit
specif
differ
patient
group
lack
correl
sever
inflamm
host
respons
support
clinic
use
reevalu
highli
sensit
biolog
assay
endotoxin
activ
assay
spectral
diagnost
inc
approv
fda
use
unit
state
ex
vivo
wholeblood
kinet
luminometr
assay
zymosan
antiendotoxinantibodi
elicit
respiratori
burst
antibodi
direct
lipopolysaccharid
variou
gramneg
bacteria
clinic
studi
assay
high
neg
predict
valu
diagnosi
gramneg
infect
shown
use
exclud
seriou
bacteri
infect
patient
admit
icu
low
respons
sever
infect
may
limit
valu
guid
therapi
also
low
specif
may
restrict
clinic
use
futur
studi
indic
whether
biomark
similar
sensit
given
low
specif
chemokin
superfamili
small
peptid
involv
leukocyt
chemotaxi
induct
cytokin
wide
rang
infecti
diseas
peptid
secret
tissu
cell
leukocyt
activ
epitheli
cell
four
differ
subfamili
identifi
base
highli
conserv
presenc
first
two
cystein
residu
either
separ
amino
acid
cc
chemokin
cxc
chemokin
chemokin
c
chemokin
chemokin
act
famili
chemokin
receptor
present
cell
type
leukocyt
dendrit
cell
endotheli
cell
chemokin
receptor
play
import
role
innat
immun
infecti
diseas
hivaid
malaria
measur
serum
level
cxc
cc
chemokin
initi
phase
meningococc
sepsi
children
predict
mortal
correl
strongli
diseas
sever
vermont
et
al
chemokin
may
play
key
role
pathophysiolog
meningococc
diseas
potenti
new
target
therapeut
approach
mitochondri
damag
dysfunct
consid
play
import
role
pathogenesi
sepsisinduc
organ
failur
unfortun
pauciti
specif
biomark
mitochondri
damag
vital
organ
recent
carbomyl
phosphat
synthas
cp
protein
primarili
local
liver
mitochondria
found
present
high
concentr
plasma
patient
sepsi
prospect
random
control
anim
studi
verifi
circul
marker
mitochondri
damag
deplet
liver
subacut
phase
sepsi
crouser
et
al
mechanist
standpoint
mitochondri
deplet
due
cell
death
appar
relat
remov
damag
mitochondria
lysosom
follow
replet
mitochondri
popul
restor
mitochondri
popul
liver
reduc
level
appear
signal
recoveri
sepsi
may
superior
convent
marker
liver
damag
sepsi
studi
need
determin
clinic
util
marker
sever
sepsi
proteom
technolog
use
detect
protein
biomark
infect
exampl
novel
mass
spectral
fingerprint
proteom
approach
use
malditof
ms
appli
detect
identifi
protein
biomark
group
streptococcu
ga
strain
moura
et
al
specif
biomark
found
strain
invas
ga
isol
could
differenti
ga
isol
case
necrot
fasciiti
cluster
togeth
distinct
isol
associ
noninvas
infect
nation
institut
allergi
infecti
diseas
nih
grant
million
univers
texa
medic
branch
utmb
galveston
seek
biomark
infecti
diseas
utmb
use
contract
establish
clinic
proteom
center
infecti
diseas
biodefens
utmb
research
search
protein
creat
pathogen
made
human
bodi
respons
infect
protein
could
use
indic
diseas
develop
diagnost
therapi
vaccin
first
two
diseas
center
studi
includ
dengu
fever
brucellosi
candid
biomark
made
publicli
avail
free
research
commun
develop
center
also
assess
sampl
submit
outsid
institut
protein
biomark
sepsi
defin
system
inflammatori
respons
syndrom
sir
identifi
focu
infect
sir
also
precipit
noninfect
event
trauma
pancreat
surgeri
consequ
overact
sir
respons
function
variou
organ
system
may
compromis
result
multipl
organ
dysfunct
syndrom
death
effort
made
identifi
biomark
prognosi
sir
chromogranin
cga
biomark
stress
releas
catecholamin
adren
medulla
previous
associ
cardiovascular
diseas
cancer
serum
cga
concentr
significantli
increas
sir
patient
compar
healthi
control
highest
increas
cga
seen
patient
infect
associ
sir
cga
concentr
posit
correl
biomark
inflamm
procalcitonin
crp
well
simplifi
acut
physiolog
score
sap
patient
cga
concentr
significantli
shorter
surviv
zhang
et
al
tuberculosi
gener
diagnos
combin
gener
specif
symptom
along
find
variou
laboratori
test
two
wide
use
test
tuberculin
skin
test
acidfast
microscop
smear
although
provid
rapid
result
neither
especi
reliabl
skin
test
distinguish
latent
infect
activ
tuberculosi
addit
distinguish
tuberculosi
atyp
mycobacterium
prove
difficult
microscop
reliabl
detect
larg
number
organ
must
present
sputum
smear
posit
onehalf
threequart
case
cultur
distinguish
mycobacteria
atyp
form
determin
antibiot
sensit
take
long
week
distinct
import
atyp
form
mycobacteria
respond
convent
antibiot
time
lag
diagnosi
howev
delay
isol
contagi
diseas
initi
treatment
emerg
multidrugresist
mdr
tuberculosi
aggrav
attempt
erad
infect
mdr
organ
resist
convent
antimicrobi
therapi
also
associ
high
mortal
rapid
occurr
death
molecular
technolog
avail
provid
detect
identif
antimicrobi
sensit
test
mycobacteria
ideal
molecular
probe
would
provid
function
directli
clinic
sampl
sensit
cultur
matter
hour
rather
week
rapid
result
essenti
provid
optim
care
patient
infect
tuberculosi
mycobacterium
speci
limit
spread
tuberculosi
fda
approv
amplifi
mycobacterium
tuberculosi
direct
amtd
test
genprob
san
diego
california
variou
studi
afb
acidfast
bacilli
smear
cultur
sensit
amtd
specif
test
combin
genprob
transcriptionmedi
amplif
hpa
technolog
yield
result
h
use
patient
cultiv
tuberculosi
continu
shed
microorgan
addit
amtd
aid
monitor
patient
treat
antitubercular
drug
largescal
studi
initi
aim
identifi
biomark
tuberculosi
infect
diseas
key
find
recent
time
one
factor
seem
abl
explain
complex
cours
tuberculosi
infect
multifactori
analys
identifi
varieti
gene
protein
mostli
involv
bacteri
persist
host
respons
offer
promis
biomark
differ
diseas
stage
candid
biomark
differenti
peopl
activ
tuberculosi
healthi
individu
normal
therapi
reproduc
predict
clinic
outcom
divers
patient
popul
walli
et
al
although
larg
number
promis
candid
biomark
examin
date
patient
studi
reach
clinic
meaning
outcom
studi
conduct
intern
research
standard
challeng
valid
suggest
biomark
describ
reduc
clinic
practic
doherti
et
al
done
offer
possibl
greatli
improv
clinic
manag
tuberculosi
allow
segreg
patient
contact
appropri
treatment
regimen
diagnosi
tubercul
mening
tbm
difficult
rapid
confirmatori
diagnosi
essenti
initi
requir
therapi
presenc
kd
heatshock
protein
hsp
antigen
csf
confirm
suspect
case
tbm
would
indic
select
protein
specif
tuberculosi
could
consid
diagnost
biomark
tbm
mudaliar
et
al
pulmonari
tuberculosi
may
alter
volatil
organ
compound
voc
breath
mycobacteria
oxid
stress
result
mycobacteri
infect
gener
distinct
voc
studi
conduct
determin
breath
voc
contain
biomark
activ
pulmonari
tuberculosi
phillip
et
al
head
space
voc
cultur
tuberculosi
captur
sorbent
trap
assay
ga
chromatographymass
spectroscopi
gcm
breath
voc
assay
gcm
patient
hospit
suspicion
pulmonari
tuberculosi
healthi
control
sputum
cultur
posit
mycobacteria
neg
patient
pattern
recognit
analysi
fuzzi
logic
analysi
breath
voc
independ
distinguish
healthi
control
hospit
patient
sensit
specif
studi
conclud
volatil
biomark
breath
sensit
specif
pulmonari
tuberculosi
breath
test
distinguish
sick
versu
well
ie
normal
control
patient
hospit
suspicion
pulmonari
tuberculosi
infect
versu
noninfect
patient
ie
whose
sputum
cultur
posit
neg
mycobacteria
howev
sinc
find
deriv
compar
small
pilot
studi
confirm
requir
addit
studi
larger
number
patient
approxim
acut
viral
hepat
case
due
familiar
hepat
virus
diagnosi
hepat
e
serolog
marker
usual
adequ
contrast
molecular
diagnosi
import
hepat
b
c
caus
hepat
infect
nearli
case
continu
baffl
physician
hepat
viru
hav
common
caus
viral
hepat
worldwid
small
singlestrand
rna
viru
belong
enteroviru
genu
picornaviru
famili
hav
infect
usual
produc
brief
ill
lead
chronic
carrier
state
chronic
hepat
pcrbase
assay
use
detect
hav
antibodi
well
differenti
genotyp
ii
addit
modifi
pcr
test
detect
intact
viru
particl
ignor
fragment
genet
materi
viru
destroy
steril
process
method
blood
product
incub
havspecif
monoclon
antibodi
viral
rna
transcrib
amplifi
identifi
dna
antibodi
captur
intact
viru
pcr
test
identifi
viral
nucleic
acid
make
falseposit
result
less
like
hepat
b
viru
hbv
approxim
million
chronic
carrier
hbv
worldwid
repres
global
healthcar
challeng
exposur
contamin
blood
major
sourc
infect
mode
transmiss
possibl
eg
inocul
ocular
surfac
corneal
transplant
chronic
hbv
infect
respons
much
world
liver
cirrhosi
implic
high
percentag
case
liver
cancer
situat
screen
viru
warrant
includ
follow
clinic
suspicion
hepat
bblood
donor
blood
productsmonitor
respons
vaccin
hbv
difficult
cultur
presenc
typic
demonstr
electron
microscopi
although
exist
hbv
surfac
antigen
hbsag
serum
plasma
indic
hbv
infect
detect
hbsag
provid
inform
replic
activ
viru
hepanostika
hbsag
ultra
assay
biomerieux
ceapprov
test
launch
europemiddl
east
offer
stateoftheart
sensit
excel
specif
detect
hbv
surfac
antigen
human
plasma
serum
level
hbv
dna
serum
plasma
probabl
reflect
replic
activ
hbv
variou
techniqu
detect
hbv
dna
develop
includ
hybrid
assay
gener
quantit
result
lack
sensit
pcr
offer
superior
sensit
predict
qualit
result
though
find
import
treatment
guid
method
quantit
assess
hbv
dna
includ
bayer
hbv
dna
assay
abbott
hbv
dna
assay
monitor
level
hbv
may
help
identifi
individu
like
respond
antivir
therapi
evalu
efficaci
therapi
track
infect
viral
burden
therapi
monitor
provid
sever
benefit
facilit
track
viral
load
reduct
enabl
earli
identif
relapseshbv
rna
level
given
time
point
predict
respons
therapyth
standard
reproduc
assay
demonstr
specimen
taken
differ
time
differ
place
clinic
trial
help
evalu
test
result
viral
hepat
diseas
especi
induc
hbv
progress
seriou
patholog
outcom
eventu
hepatocellular
carcinoma
grow
bodi
evid
indic
mani
trace
element
play
import
role
number
carcinogen
process
proceed
variou
mechan
markedli
elev
cu
zn
ratio
found
patient
hepat
cirrhosi
hepatocellular
carcinoma
find
impli
level
trace
element
selenium
iron
copper
zinc
cu
zn
ratio
might
serv
biomark
increas
sever
viral
hepat
damag
lin
et
al
hepat
c
viru
hcv
hcv
affect
roughli
million
peopl
around
world
approxim
million
person
chronic
hcv
infect
unit
state
new
infect
diagnos
year
infect
patient
die
europ
number
patient
chronic
hcv
infect
estim
million
number
hcvantibodyposit
individu
high
million
acut
hcv
infect
develop
chronic
diseas
case
set
stage
develop
liver
cirrhosi
hepatocellular
carcinoma
introduct
approv
immunoassay
eia
reduc
incid
hcv
transmiss
via
blood
transfus
first
test
administ
patient
clinic
liver
diseas
anoth
test
avail
hcv
immunoblot
assay
method
limit
use
howev
period
sever
week
separ
infect
seroconvers
addit
loss
antibodi
persist
infect
individu
report
anoth
monitor
method
measur
level
liver
enzym
alanin
aminotransferas
alt
also
give
mislead
result
fluctuat
correl
level
hcv
exampl
alt
level
may
normal
therapi
despit
persist
detect
level
hcv
rna
hepat
damag
minim
develop
yet
alt
level
may
remain
normal
activ
hcv
infect
ill
hcv
eg
alcohol
may
also
produc
abnorm
alt
valu
complic
diagnosi
direct
detect
hcv
valuabl
follow
situat
diagnosi
neonat
born
seroposit
motherdiagnosi
hcv
infect
seroneg
individualsdiagnosi
organ
transplant
recipientsassess
antivir
therapi
interferonalpha
although
recommend
treatment
chronic
hcv
infect
involv
cours
combin
ribavirin
rbv
therapi
cure
hcv
respons
even
lower
africanamerican
popul
addit
limit
efficaci
treatment
often
poorli
toler
side
effect
prevent
patient
complet
therapi
reason
identif
biomark
respons
treatment
high
prioriti
genet
polymorph
near
gene
encod
report
associ
approxim
twofold
chang
respons
treatment
among
patient
european
ancestri
africanamerican
ge
et
al
almost
favor
respons
genotyp
erad
viru
less
favor
respons
genotyp
genotyp
lead
better
respons
substanti
greater
frequenc
european
african
popul
genet
polymorph
also
explain
approxim
half
differ
respons
rate
africanamerican
patient
european
ancestri
hand
among
africanamerican
carri
cc
genotyp
treatment
respons
higher
treatment
respons
observ
among
individu
european
descent
tt
genotyp
favor
c
allel
also
tend
found
less
frequent
chronic
hcv
infect
suggest
role
overal
viral
clearanc
unexpectedli
though
author
report
c
allel
actual
appear
link
higher
rather
lower
baselin
viral
load
research
need
determin
whether
newli
identifi
snp
biomark
import
genet
chang
whether
chang
directli
influenc
treatment
outcom
sar
sever
acut
respiratori
syndrom
associ
coronaviru
sarscov
confirm
pathogen
sar
sever
compani
work
develop
diagnost
sar
viru
base
detect
viru
cytokin
growth
factor
biomark
import
indic
inflammatori
respons
infect
cytokin
profil
also
provid
use
tool
diagnosi
manag
sar
acut
infect
caus
rapid
increas
cytokin
level
exagger
respons
high
viral
load
detriment
individu
huge
elev
varieti
cytokin
biomark
may
alert
clinician
sever
infect
ensur
prioriti
patient
manag
immedi
prevent
spread
biomark
elev
sar
ifng
cytokin
respons
shown
affect
mortal
morbid
patient
communic
diseas
biochip
array
technolog
randox
laboratori
offer
blood
test
system
offer
rapid
cytokin
profil
patient
sampl
system
use
panel
approach
diagnost
profil
enabl
simultan
measur
numer
marker
minut
easeofus
minim
oper
intervent
key
benefit
system
measur
quantifi
mani
clinic
marker
risk
infect
laboratori
personnel
limit
sampl
handl
fulli
autom
onboard
dispos
compart
ensur
isol
contamin
wast
system
boast
test
throughput
cytokin
test
result
per
hour
enabl
rapid
profil
numer
patient
within
time
constraint
regul
major
caus
aid
world
retroviru
hiv
type
worldwid
estim
million
person
infect
hiv
includ
million
individu
unit
state
hiv
infect
predominantli
sexual
transmit
disord
although
mode
transmiss
eg
infect
blood
transfus
intraven
drug
abus
via
infect
needl
well
recogn
direct
detect
difficult
small
number
cell
harbor
viru
small
number
provir
copi
exist
infect
cell
viral
genom
tendenc
toward
transcript
dormanc
nevertheless
number
assay
develop
detect
presenc
infect
quantifi
level
viru
blood
infect
individu
eia
test
detect
quantif
antigenwestern
blotlatex
agglutinationradioimmunoprecipitationimmunofluoresc
detect
antibodi
cultur
isol
semiquantif
hivassoci
neuropsycholog
impair
frequent
among
patient
incid
hiv
dementia
declin
sinc
introduct
haart
therapi
zidovudin
lamivudin
ritonavir
boost
indinavir
improv
neurocognit
function
parallel
normal
csf
neural
marker
nfl
tau
gfap
level
declin
csf
serum
neopterin
csf
plasma
rna
level
andersson
et
al
apolipoprotein
b
mrnaedit
enzym
catalyt
polypeptidelik
also
known
novel
cellular
factor
innat
immun
inhibit
hiv
replic
vitro
caus
g
hypermut
consequ
reduc
rel
infect
viru
produc
infect
cell
quantif
mrna
level
patient
sampl
prognost
indic
innat
hivaid
diseas
resist
predict
whether
viralinfect
patient
categor
longterm
nonprogressor
ltnp
much
slower
diseas
progress
rate
jin
et
al
also
provid
method
predict
level
cell
patient
well
method
optim
antivir
therapi
viralinfect
patient
signific
implic
new
develop
diagnost
tool
therapeut
target
treat
viral
infect
incid
sever
malaria
infect
continu
rise
mani
part
world
situat
exacerb
emerg
multidrug
resist
plasmodium
falciparum
plasmodium
vivax
two
import
human
malaria
parasit
malaria
complex
infecti
diseas
host
respons
infect
depend
parasit
stage
parasit
virul
factor
host
genet
background
diagnosi
establish
identif
parasit
blood
smear
still
need
understand
molecular
process
regul
transcript
activ
gene
network
involv
pathogenesi
protect
diseas
may
provid
insight
protect
mechan
immun
aid
design
effect
vaccin
analysi
gene
express
profil
identifi
set
host
biomark
distinguish
lethal
nonleth
blood
stage
murin
malaria
infect
plamodium
yoelii
schaecher
et
al
multipl
biolog
replic
sampl
cours
infect
use
establish
statist
valid
set
differenti
express
gene
gene
correl
intens
infect
use
identifi
pathway
cellular
process
relat
metabol
perturb
erythropoiesi
bcell
immun
respons
innat
cellular
immun
respons
provid
insight
transcript
regulatori
mechan
influenc
pathogenesi
diseas
host
recoveri
infect
immun
respons
human
p
falciparum
p
vivax
malaria
may
share
mani
similar
featur
global
gene
express
program
observ
murin
malaria
import
differ
express
profil
human
infect
clinic
experiment
malaria
depend
type
tissu
peripher
blood
bone
marrow
spleen
brain
stage
infect
earli
asymptomat
versu
clinic
malaria
studi
acquisit
mainten
antimalari
antibodi
depend
exposur
malaria
infect
antibodi
might
use
biomark
transmiss
intens
measur
antibodi
serolog
test
may
detect
variat
malaria
transmiss
time
invalu
monitor
trend
malaria
endem
effect
malaria
control
program
molecular
biomark
investig
assess
resist
antimalari
drug
conclus
inform
avail
yet
effort
use
plasma
level
circul
parasit
dna
estim
sequest
load
p
falciparum
success
far
import
identifi
individu
infect
p
falciparum
risk
develop
seriou
complic
cerebr
malaria
serum
ratio
promis
clinic
inform
biomark
cerebr
malaria
lovegrov
et
al
studi
address
use
prognost
biomark
potenti
therapeut
target
sever
malaria
schistosomiasi
second
preval
human
parasit
diseas
malaria
affect
million
peopl
worldwid
egg
produc
infect
schistosoma
mansoni
produc
complex
uniqu
protein
lipidlink
glycan
import
activ
modul
host
immun
respons
current
diagnosi
schistosomiasi
ideal
egg
detect
microscopi
specif
lack
sensit
suffer
highli
fluctuat
egg
output
antibodybas
diagnosi
sensit
fail
reliabl
identifi
activ
infect
antigen
detectionbas
assay
number
advantag
fail
detect
minim
infect
prompt
search
biomark
diseas
scientist
discov
addit
glycoprotein
glycolipid
antigen
schistosoma
egg
also
excret
uniqu
unconjug
oligosaccharid
identifi
use
affin
purif
method
base
specif
antiglycan
mab
oligosaccharid
appear
biomark
infect
urin
infect
individu
detect
mass
spectrometri
identif
new
smallmolecul
biomark
may
lead
new
eggloadrel
assay
light
infect
schistosomiasi
may
also
use
measur
infect
morbid
breath
biomark
potenti
offer
inform
similar
convent
clinic
test
entir
uniqu
preliminari
data
support
use
breath
biomark
studi
liver
diseas
particular
nonalcohol
fatti
liver
diseas
solga
et
al
evalu
whether
breath
ethanol
ethan
sulfur
compound
aceton
would
associ
hepat
histopatholog
among
morbidli
obes
patient
present
bariatr
surgeri
breath
sampl
collect
preoper
visit
compar
liver
biopsi
obtain
surgeri
student
twotail
ttest
use
compar
differ
two
group
linear
regress
use
analyz
associ
concentr
breath
molecul
independ
predictor
variabl
found
breath
ethanol
ethan
aceton
use
biomark
patient
nonalcohol
fatti
liver
diseas
particular
breath
ethanol
associ
hepat
steatosi
breath
aceton
associ
nonalcohol
steatohepat
histolog
examin
liver
biopsi
specimen
regard
refer
standard
detect
liver
fibrosi
biopsi
pain
hazard
assess
subject
prone
sampl
error
among
noninvas
altern
liver
biopsi
sever
studi
demonstr
predict
valu
superior
benefitrisk
ratio
biopsi
two
combin
simpl
serum
biochem
marker
patient
infect
hepat
b
viru
hbv
hepat
c
viru
hcv
includ
fibrotest
biopredict
quantit
assess
fibrosi
actitest
biopredict
quantit
assess
necroinflammatori
activ
hcvfibrosur
labcorp
test
avail
sever
countri
facilit
screen
manag
frequent
liver
diseas
biomark
investig
panel
sensit
autom
immunoassay
develop
detect
matrix
constitu
mediat
matrix
remodel
serum
evalu
perform
biomark
detect
liver
fibrosi
comparison
biopsi
specimen
obtain
subject
chronic
liver
diseas
fibrosi
stage
rosenberg
et
al
discrimin
analysi
test
set
sampl
use
identifi
algorithm
combin
age
hyaluron
acid
aminotermin
propeptid
type
iii
collagen
piiinp
tissu
inhibitor
matrix
metalloproteinas
subsequ
evalu
use
valid
set
biopsi
specimen
serum
sampl
algorithm
detect
fibrosi
sensit
accur
detect
absenc
fibrosi
neg
predict
valu
signific
fibrosi
perform
excel
alcohol
liver
diseas
nonalcohol
fatti
liver
diseas
algorithm
perform
equal
well
comparison
pathologist
contrast
pathologist
agreement
histolog
score
rang
good
moder
conclud
assess
liver
fibrosi
multipl
serum
marker
use
combin
sensit
specif
reproduc
suggest
may
use
conjunct
liver
biopsi
assess
rang
chronic
liver
diseas
studi
basi
test
iqur
ltd
serum
biomark
liver
fibrosi
hyaluron
acid
piiinp
studi
document
respons
lamivudin
patient
chronic
hbv
period
use
surrog
serum
biomark
without
corrobor
histolog
data
poynard
et
al
investig
found
improv
fibrosi
inflamm
respect
despit
emerg
ymdd
mutat
patient
higher
improv
rate
report
studi
interpret
caution
number
reason
includ
absenc
data
virolog
respons
rate
correspond
histolog
data
data
valid
ft
evalu
fibrosi
longitudin
manner
although
ft
studi
extens
author
current
studi
date
independ
studi
addit
signific
interlaboratori
variat
studi
shown
signific
fibrosi
could
miss
convers
signific
fibrosi
diagnos
absenc
minim
fibrosi
patient
collagen
iv
compon
basement
membran
releas
blood
basement
membran
turnov
increas
deposit
collagen
associ
increas
serum
level
collagen
iv
serum
iv
may
earli
specif
biomark
activ
fibrosi
particularli
alcohol
liver
diseas
hepat
c
elev
serum
collagen
iv
level
also
associ
resist
interferon
therapi
anoth
studi
hcvinfect
hemophilia
patient
ft
correctli
identifi
clinic
advanc
minim
liver
diseas
maor
et
al
discord
among
variou
biomark
fibrosi
consider
nevertheless
practic
combin
ft
asttoplatelet
ratio
index
forn
may
predict
stage
fibrosi
accuraci
potenti
avoid
liver
biopsi
major
patient
alpha
glutathion
stransferas
alpha
gst
uniqu
sensit
specif
biomark
hepatocyt
injuri
unlik
aminotransferas
predominantli
found
periport
hepatocyt
alpha
gst
found
hepatocyt
alpha
gst
found
hepatocyt
throughout
periport
centrilobular
region
liver
uniform
hepat
distribut
togeth
high
intracellular
level
short
halflif
min
mean
alpha
gst
sensit
specif
indic
hepatocyt
injuri
situat
hepatox
transplant
injuri
hepat
current
gold
standard
liver
cirrhosi
detect
invas
costli
often
pain
liver
biopsi
therefor
need
biomark
could
obviat
biopsi
cirrhosi
patient
high
serum
level
tropomyosin
demonstr
patient
hepat
cirrhosi
due
differ
caus
use
proteom
approach
et
al
quantit
analysi
serum
level
larg
number
patient
show
novel
candid
biomark
high
diagnost
accuraci
predict
nondiseas
liver
versu
cirrhosi
limit
combin
five
algorithm
test
measur
level
liver
measur
activ
liver
measur
hepat
steatosi
fatti
liver
measur
level
nonalcohol
use
monitor
liver
damag
case
sever
alcohol
steatohepat
use
uniqu
combin
serum
biomark
plu
age
gender
weight
height
data
enter
patent
algorithm
accur
determin
level
liver
diseas
without
need
undertak
invas
liver
biopsi
global
hcv
patient
clinic
manag
use
altern
liver
biopsi
compar
studi
patient
alcohol
liver
diseas
biomark
fibrometera
hepascor
improv
diagnost
prognost
valu
fibrotest
naveau
et
al
acut
pancreat
acut
inflamm
pancrea
common
caus
gallston
alcohol
abus
condit
rang
mild
life
threaten
sever
condit
may
obviou
present
key
event
develop
sever
pancreat
activ
proenzym
pancrea
import
trypsinogen
trypsinogen
convert
activ
trypsin
lyse
pancreat
tissu
releas
pancreat
enzym
lead
tissu
necrosi
inflamm
activ
trypsinogen
small
peptid
trypsinogen
activ
peptid
tap
split
trypsinogen
presenc
bodi
fluid
sensit
specif
indic
sever
acut
pancreat
tap
better
discrimin
sever
acut
acut
pancreat
laboratori
test
eg
amylas
lipas
tap
difficult
measur
requir
sensit
immunoassay
techniqu
tap
assay
biotrin
valuabl
follow
situat
monitor
effect
differ
therapi
acut
pancreatitisinvestig
effect
surgeri
pancreasinvestig
toxic
effect
drug
pancrea
eg
antihiv
therapystag
subject
studi
pancreat
cystatin
c
nonglycosyl
protein
low
molecular
weight
kda
cystatin
superfamili
produc
constant
rate
nucleat
cell
cystatin
c
belong
cystein
proteinas
inhibitor
group
associ
sever
patholog
condit
imbal
cystatin
c
cystein
proteinas
associ
diseas
inflamm
renal
failur
cancer
alzheim
diseas
amyotroph
later
sclerosi
multipl
sclerosi
hereditari
cystatin
c
amyloid
angiopathi
cystatin
c
remov
blood
plasma
glomerular
filtrat
kidney
reabsorb
proxim
tubular
cell
degrad
linear
relationship
reciproc
cystatin
c
concentr
plasma
glomerular
filtrat
rate
gfr
cystatin
c
suggest
better
biomark
gfr
marker
serum
concentr
affect
factor
age
gender
bodi
mass
associ
cystatin
c
level
incid
myocardi
infarct
coronari
death
present
risk
factor
secondari
cardiovascular
event
cystatin
c
immunoassay
kit
lumino
llc
ann
arbor
mi
design
measur
cystatin
c
level
kit
use
nativ
human
cystatin
c
molecul
standard
acut
kidney
injuri
aki
previous
refer
acut
renal
failur
import
problem
clinic
medicin
despit
signific
improv
therapeut
mortal
morbid
associ
aki
remain
high
reason
includ
incomplet
understand
underli
pathophysiolog
mechan
b
lack
earli
biomark
aki
henc
unaccept
delay
initi
therapi
applic
function
genom
proteom
human
anim
model
aki
uncov
sever
novel
gene
protein
emerg
biomark
novel
therapeut
target
identif
protein
biomark
plasma
ngal
cystatin
c
urin
ngal
cystatin
c
alpha
fetuina
groalpha
meprin
hold
promis
investig
ischem
aki
devarajan
like
aki
panel
use
time
initi
insult
assess
durat
aki
base
differenti
express
biomark
also
like
aki
panel
distinguish
variou
caus
aki
predict
clinic
outcom
system
lupu
erythematosu
affect
kidney
may
sometim
lead
endstag
renal
diseas
lupu
nephriti
divid
six
class
score
accord
activ
chronic
indic
base
histolog
find
treatment
differ
base
patholog
find
renal
biopsi
current
way
accur
predict
class
activ
chronic
indic
sever
protein
identifi
urin
sampl
patient
lupu
nephriti
use
biomark
indic
type
sever
renal
diseas
patient
well
extent
damag
kidney
assay
base
antibodi
spot
could
elimin
need
renal
biopsi
allow
frequent
evalu
diseas
statu
begin
specif
therapi
patient
lupu
nephriti
studi
need
determin
whether
urin
protein
analysi
could
replac
use
biopsi
assess
kidney
damag
lupu
clinic
manag
therapeut
intervent
earlier
stage
diabet
nephropathi
dn
major
import
prevent
progress
endstag
renal
diseas
current
measur
albumin
urin
use
standard
noninvas
test
diagnosi
earli
dn
test
howev
detect
kidney
diseas
case
therefor
effort
made
find
better
diagnost
biomark
dn
proteom
approach
isol
potenti
biomark
dn
investig
identifi
sever
protein
use
diagnost
biomark
dn
includ
urinari
immunoglobulin
g
transferrin
ceruloplasmin
serum
cystatin
c
summari
diagnost
biomark
develop
last
decad
comment
impact
diagnosi
manag
diseas
publish
ito
et
al
oxid
stress
hallmark
variou
chronic
inflammatori
lung
diseas
increas
concentr
ro
lung
patient
reflect
elev
concentr
oxid
stress
marker
breath
airway
lung
tissu
blood
tradit
measur
biomark
involv
invas
procedur
procur
sampl
examin
affect
compart
patient
discomfort
noninvas
approach
measur
oxid
stress
investig
collect
exhal
breath
condens
ebc
noninvas
sampl
method
realtim
analysi
evalu
oxid
stress
biomark
lower
respiratori
tract
airway
biomark
oxid
stress
malondialdehyd
antioxid
glutathion
nitros
stress
nitratenitrit
nitros
speci
success
measur
ebc
oxid
stress
biomark
also
measur
variou
antioxid
diseas
prognosi
ebc
current
use
research
diagnost
tool
free
radic
research
yield
inform
redox
disturb
degre
type
inflamm
lung
expect
ebc
exploit
detect
specif
level
biomark
monitor
diseas
sever
respons
treatment
acut
respiratori
distress
syndrom
ard
rapid
onset
respiratori
failur
inabl
adequ
oxygen
blood
often
occur
critic
ill
acut
lung
injuri
ali
preced
ard
sever
respiratori
ill
progress
condit
life
threaten
largescal
multicent
trial
patient
ard
ali
higher
level
nitric
oxid
urin
strongli
associ
improv
surviv
ventilatorfre
day
decreas
rate
organ
failur
mcclintock
et
al
author
specul
benefici
effect
ali
sinc
scaveng
oxygenfre
radic
gener
oxid
stress
sinc
increas
microcircul
help
better
perfus
tissu
bed
lung
investig
offer
altern
hypothesi
explain
find
creat
insid
bodi
may
benefici
effect
organ
lung
ali
might
help
prevent
tissu
damag
improv
oxygen
nutrient
deliveri
tissu
help
decreas
amount
toxic
oxygen
speci
author
also
specul
might
antibacteri
effect
could
import
infecti
condit
predispos
patient
ali
plasma
biomark
relat
inflamm
enhanc
neutrophil
recruit
lung
independ
associ
increas
mortal
patient
ali
higher
level
independ
predict
death
mcclintock
et
al
addit
lower
level
coagul
marker
protein
c
independ
associ
increas
risk
death
associ
lower
protein
c
level
nonsurvivor
continu
support
role
disord
coagul
aliard
associ
exist
despit
consist
use
lung
protect
ventil
persist
even
control
clinic
factor
also
impact
upon
outcom
two
biomark
independ
associ
mortal
need
studi
potenti
valu
stratifi
patient
clinic
trial
patholog
chang
sever
acut
respiratori
syndrom
sar
suggest
sar
sequela
associ
dysregul
cytokin
chemokin
product
studi
taiwan
show
cytokin
chemokin
profil
patient
sar
differ
markedli
patient
communityacquir
pneumonia
cap
control
group
chien
et
al
serum
level
three
cytokin
significantli
elev
sar
patient
versu
cap
interleukin
il
cytokin
level
began
rise
develop
chest
involv
peak
earlier
lung
injuri
assess
chest
xray
convers
cap
patient
sar
patient
control
level
elev
rose
tandem
radiograph
chang
differ
group
ratio
sar
patient
versu
cap
patient
howev
set
patient
level
correl
strongli
sever
lung
injuri
earli
induct
well
subsequ
overproduct
lack
probabl
contribut
main
immunopatholog
process
involv
sar
lung
injuri
may
earli
biomark
lung
injuri
find
differ
observ
subject
cap
decreas
express
vascular
endotheli
growth
factor
vegf
receptor
implic
pathogenesi
copd
level
placenta
growth
factor
plgf
anoth
angiogen
factor
increas
serum
bronchoalveolar
lavag
bal
fluid
patient
copd
invers
correl
cheng
et
al
serum
level
plgf
patient
copd
doubl
smoker
nonsmok
without
copd
find
suggest
bronchial
epitheli
cell
express
plgf
may
contribut
pathogenesi
copd
plgf
vegf
express
level
increas
cultur
bronchial
epitheli
cell
expos
proinflammatori
cytokin
although
mechan
underli
observ
detriment
effect
plgf
remain
clarifi
persist
plgf
express
might
advers
effect
lung
parenchyma
downregul
angiogenesi
studi
reveal
serum
level
neuroendocrin
activ
biomark
chromagranin
cga
increas
male
smoker
impair
lung
function
associ
respiratori
symptom
degre
airway
obstruct
sorhaug
et
al
subgroup
airway
epitheli
cell
belong
diffus
neuroendocrin
system
term
pulmonari
neuroendocrin
cell
may
repres
put
regulatori
function
cga
prohormon
consid
control
growth
develop
fetal
lung
regul
ventil
circul
may
also
role
pathogenesi
smokinginduc
airway
diseas
find
indic
neuroendocrin
activ
may
import
smokingrel
airway
inflamm
remodel
rais
possibl
cga
could
predict
valu
biomark
prognosi
smokingassoci
diseas
circul
bnp
level
evalu
paramet
presenc
sever
pulmonari
hypertens
ph
patient
chronic
lung
diseas
leucht
et
al
followup
time
approxim
year
signific
pulmonari
hypertens
mean
pulmonari
arteri
pressur
mmhg
diagnos
onefourth
patient
led
decreas
exercis
toler
life
expect
elev
bnp
concentr
identifi
signific
pulmonari
hypertens
sensit
specif
predict
mortal
moreov
bnp
serv
risk
factor
death
independ
lung
function
impair
hypoxemia
conclud
plasma
bnp
facilit
noninvas
detect
signific
ph
high
accuraci
use
screen
test
presenc
ph
addit
bnp
enabl
assess
relev
ph
could
serv
use
prognost
paramet
chronic
lung
diseas
aat
plasma
glycoprotein
inhibit
neutrophil
elastas
individu
inherit
alter
aat
gene
result
defici
protein
high
risk
copd
liver
cirrhosi
defici
detect
serum
protein
pattern
studi
past
test
defici
done
retrospect
patient
copd
liver
diseas
introduct
homeadminist
fingerstick
blood
spot
test
aat
genotyp
enabl
affect
famili
construct
pedigre
enabl
identifi
children
risk
develop
copd
later
life
avoid
exposur
dust
smoke
strang
et
al
airway
inflamm
associ
increas
express
releas
inflammatori
reactant
regul
process
cell
migrat
activ
degranul
one
studi
done
quantifi
bronchial
lavag
bal
fluid
serum
level
secretori
leukocyt
proteas
inhibitor
slpi
solubl
intracellular
adhes
surrog
marker
inflammatori
immun
respons
asthma
copd
patient
similar
diseas
durat
time
holland
et
al
biomark
measur
use
commerci
avail
elisa
kit
find
show
four
measur
biomark
bal
higher
copd
patient
compar
asthma
airway
hyperrespons
main
featur
asthma
defin
increas
eas
degre
airway
narrow
respons
brochoconstrictor
stimuli
inflamm
play
central
role
pathogenesi
asthma
much
attribut
helper
tcell
type
cytokin
activ
degre
strongli
correl
diseas
sever
one
inflammatori
mediat
asthma
nitric
oxid
exhal
level
elev
asthma
predict
asthma
exacerb
heinen
et
al
averag
exhal
concentr
significantli
increas
subject
season
allerg
asthma
pollen
season
compar
season
may
clinic
use
compar
exhal
valu
subject
previou
valu
compar
populationbas
normal
rang
cough
variant
asthma
cva
atop
cough
present
bronchodilatorresist
nonproduct
cough
may
differenti
caus
chronic
nonproduct
cough
measur
exhal
exhal
level
patient
atop
cough
significantli
lower
patient
cva
bronchial
asthma
fujimura
et
al
signific
differ
exhal
level
patient
cva
bronchial
asthma
uk
studi
find
show
feasibl
measur
bronchial
flux
concentr
jno
alveolar
concentr
calv
children
calv
level
potenti
reflect
alveolar
inflamm
asthma
paraskaki
et
al
calv
jno
measur
fraction
exhal
multipl
exhal
flow
rate
asthmat
children
although
jno
give
essenti
inform
calv
higher
asthmat
children
normal
children
studi
also
highlight
relationship
poor
control
asthma
calv
biomark
alveolar
inflamm
work
need
confirm
relev
research
univers
pittsburgh
pennsylvania
develop
novel
nanosensor
detect
possibl
asthma
attack
begin
minut
sensor
fit
handheld
devic
person
blow
devic
measur
content
breath
use
devic
would
provid
asthma
suffer
simpl
costeffect
way
monitor
asthma
inflamm
explan
increas
level
exhal
nonenzymat
gener
nitrit
due
airway
acidif
asthmat
reduc
arginin
avail
may
also
contribut
lung
injuri
promot
format
cytotox
radic
peroxynitrit
arginin
level
declin
nitric
oxid
synthas
no
begin
gener
superoxid
lieu
therebi
favor
consumpt
via
gener
peroxynitrit
could
induc
lung
injuri
reduct
bioavail
via
format
speci
peroxynitrit
could
amplifi
rapid
loss
sod
activ
asthmat
respons
plasma
arginas
activ
declin
significantli
treatment
improv
symptom
addit
studi
need
determin
whether
measur
plasma
arginas
activ
provid
use
biomark
underli
metabol
disord
efficaci
treatment
diseas
arginas
activ
present
serum
probabl
accur
reflect
whole
bodi
arginas
activ
compartment
lung
sinc
arginas
intracellular
enzym
arginas
induc
monocyt
respons
helper
tcell
type
cytokin
specul
cell
one
like
sourc
elev
arginas
serum
consist
local
arginas
express
within
macrophag
lung
although
exhal
clinic
use
biomark
eosinophil
airway
inflamm
asthma
signific
valid
investig
requir
exhal
breath
condens
could
util
make
decis
clinic
practic
simpson
wark
sever
asthma
character
elev
level
proinflammatori
cytokin
neutrophil
inflamm
airway
blood
cytokin
biomark
system
inflamm
may
featur
increas
inflamm
sever
asthma
one
studi
found
level
higher
sever
asthmat
asthmat
control
conjunct
augment
circul
neutrophil
suggest
involv
neutrophilderiv
cytokin
pattern
silvestri
et
al
furthermor
patient
sever
asthma
level
posit
correl
exhal
nitric
oxid
circul
neutrophil
count
cytokin
level
elev
even
though
patient
highdos
inhal
steroid
find
might
reflect
inabl
drug
significantli
suppress
product
cytokin
airway
cellular
sourc
includ
epitheli
cell
inflammatori
cell
patient
sever
asthma
may
imbal
product
block
capac
autoantibodi
find
studi
may
clinic
relev
suggest
drug
block
releas
activ
might
repres
new
treatment
option
sever
asthma
clinic
observ
suggest
rhinoviru
infect
induc
specif
inflammatori
respons
predispos
individu
result
worsen
asthmat
symptom
increas
airway
inflamm
studi
shown
protein
ip
specif
releas
acut
virusinduc
asthma
measur
serum
predict
viral
trigger
acut
exacerb
wark
et
al
primari
bronchial
epitheli
cell
model
rhinoviru
infect
use
identifi
mediat
rhinoviru
infect
respond
infect
releas
high
level
rant
well
smaller
amount
perhap
combin
might
use
clinic
marker
identifi
rhinoviru
virusinduc
acut
asthma
addit
find
suggest
receptor
highli
express
activ
cell
might
role
worsen
airflow
obstruct
airway
inflamm
may
therefor
potenti
therapeut
target
intern
guidelin
manag
asthma
support
earli
introduct
corticosteroid
control
symptom
improv
lung
function
reduc
airway
inflamm
howev
individu
respond
corticosteroid
extent
would
desir
abl
predict
respons
corticosteroid
treatment
sever
biomark
assess
follow
treatment
corticosteroid
includ
measur
lung
function
peripher
blood
sputum
indic
inflamm
exhal
gase
breath
condens
wide
examin
measur
predict
respons
corticosteroid
airway
hyperrespons
exhal
eno
induc
sputum
sputum
eosinophilia
demonstr
best
predictor
shortterm
respons
corticosteroid
importantli
direct
treatment
normal
sputum
eosinophil
count
substanti
reduc
sever
exacerb
widespread
util
sputum
induct
hamper
procedur
rel
labor
intens
measur
eno
simpler
incorpor
assess
asthma
manag
strategi
led
reduct
exacerb
rate
challeng
either
simplifi
measur
sputum
eosinophilia
identifi
anoth
inflammatori
biomark
similar
efficaci
sputum
eosinophil
count
predict
short
longterm
respons
corticosteroid
ige
play
central
role
pathophysiolog
asthma
two
essenti
phase
pathophysiolog
sensit
allergen
clinic
express
symptom
reexposur
sensit
allergen
omalizumab
xolair
genentech
recombin
human
monoclon
antiig
antibodi
bind
circul
ige
regardless
allergen
specif
form
small
biolog
inert
ige
antiig
complex
without
activ
complement
cascad
reduct
free
serum
ige
ie
ige
bound
omalizumab
occur
soon
administr
omalizumab
low
level
persist
throughout
treatment
appropri
dose
total
serum
ige
level
measur
patient
consid
treatment
omalizumab
dose
omalizumab
determin
basi
ige
level
bodi
weight
strunk
bloomberg
dose
base
estim
amount
drug
requir
reduc
circul
free
ige
level
less
iuml
endothelin
proinflammatori
profibrot
broncho
vasoconstrict
peptid
play
import
role
develop
airway
inflamm
remodel
asthma
studi
evalu
level
exhal
breath
condens
ebc
asthmat
differ
degre
asthma
sever
zietkowski
et
al
concentr
ebc
asthmat
patient
significantli
higher
healthi
volunt
level
significantli
higher
patient
unstabl
asthma
two
group
stabl
diseas
thu
measur
ebc
may
provid
anoth
use
diagnost
tool
detect
monitor
inflamm
patient
asthma
releas
bronchial
epithelium
influenc
mani
inflammatori
cell
essenti
asthma
interact
cytokin
may
play
import
role
increas
airway
inflamm
observ
postexercis
bronchoconstrict
asthmat
patient
cystic
fibrosi
cf
common
seriou
genet
diseas
among
caucasian
unit
state
diseas
result
defect
gene
affect
multipl
aspect
cellular
function
seriou
symptom
buildup
thick
sticki
mucu
airway
lead
fatal
lung
infect
usual
method
screen
diagnosi
genotyp
cystic
fibrosi
transmembran
conduct
regul
cftr
gene
mutat
antibodi
microarray
develop
platform
identifi
cfspecif
serum
proteom
signatur
srivastava
et
al
serum
sampl
cf
patient
pool
compar
equival
pool
control
sera
order
identifi
pattern
protein
express
uniqu
cf
set
significantli
differenti
express
protein
enrich
protein
mediat
inflamm
nfkappab
signal
pathway
protein
may
select
express
cfaffect
tissu
lung
intestin
sever
instanc
data
antibodi
microarray
valid
quantit
analysi
revers
captur
protein
microarray
conclus
antibodi
microarray
technolog
sensit
quantit
robust
use
proteom
platform
discrimin
sera
cf
control
patient
extens
protein
degrad
differenti
express
protein
identifi
sputum
biomark
inflamm
relat
pulmonari
exacerb
cf
sloan
et
al
manag
venou
thromboembol
past
character
high
degre
complex
lack
efficaci
effici
nonspecif
clinic
sign
acut
pulmonari
embol
pe
limit
earlier
imag
procedur
led
develop
numer
sophist
multistep
diagnost
algorithm
howev
prove
extrem
difficult
implement
clinic
practic
diagnosi
potenti
lifethreaten
pe
still
miss
mani
patient
subsequ
die
diseas
without
receiv
appropri
treatment
patient
unnecessarili
undergo
invas
timeconsum
procedur
due
vagu
poorli
document
clinic
suspicion
widespread
use
ddimer
test
outpati
set
particularli
technic
advanc
multidetectorrow
ct
scan
enorm
impact
strategi
approach
patient
suspect
pe
ddimer
test
origin
develop
diagnosi
dissemin
intravascular
coagul
later
turn
use
thromboembol
disord
ddimer
uniqu
breakdown
product
fibrin
mesh
stabil
factor
xiii
crosslink
eelement
two
delement
final
step
gener
thrombu
ddimer
elisa
assay
reli
mab
bind
specif
protein
fragment
ddimer
also
use
monitor
anticoagul
therapi
pulmonari
embol
patient
abnorm
ddimer
level
month
discontinu
anticoagul
signific
incid
recurr
venou
thromboembol
reduc
resumpt
anticoagul
palareti
et
al
optim
cours
anticoagul
patient
normal
ddimer
level
clearli
establish
combin
use
brain
natriuret
peptid
bnp
cardiac
troponin
ctnt
may
use
risk
stratif
normotens
patient
acut
pulmonari
embol
patient
increas
bnp
ctnt
risk
advers
outcom
futur
studi
larger
number
patient
need
confirm
use
biomark
clinic
manag
individu
patient
pulmonari
embol
studi
compar
respect
prognost
valu
biomark
nonmass
pe
carri
predict
advers
outcom
month
vuilleumi
et
al
combin
outcom
consist
need
intens
care
monitor
admiss
death
hospit
attribut
either
perel
complic
defin
pedvt
relaps
major
bleed
anticoagul
dyspnea
without
chest
pain
followup
outcom
met
patient
univari
analysi
ntprobnp
level
pgml
strongest
predictor
unfavor
outcom
neg
predict
valu
cutoff
true
neg
rate
ntprobnp
multivari
analysi
ntprobnp
signific
independ
predictor
therefor
ntprobnp
use
biomark
risk
stratif
identifi
lowrisk
patient
nonmass
pe
could
treat
outpati
set
protein
biomark
urin
pregnant
women
could
serv
screeningdiagnost
tool
preeclampsia
mani
protein
present
serum
blood
could
provid
clue
preeclampsia
relationship
diagnost
signific
algorithm
use
calcul
ratio
presenc
absenc
three
specif
protein
normal
secret
human
placenta
ratio
two
protein
correctli
identifi
women
sever
preeclampsia
adachi
et
al
protein
vascular
endotheli
growth
factor
vegf
placent
growth
factor
plgf
solubl
vegf
receptor
ratio
plgf
high
sensit
specif
identifi
sever
preeclampsia
accur
proteinuria
alon
panel
biomark
present
urin
could
distinguish
pregnant
women
preeclampsia
healthi
pregnant
women
combin
presenc
two
biomark
specif
fragment
albumin
highli
characterist
preeclampsia
superimpos
chronic
hypertens
marker
panel
assay
use
vermillion
selditof
technolog
could
classifi
studi
subject
accuraci
develop
new
test
use
biomark
could
lead
earlier
diagnosi
treatment
preeclampsia
help
prevent
prematur
birth
one
studi
use
proteom
analysi
csf
identifi
protein
biomark
characterist
preeclampsia
relat
sever
norwitz
et
al
sampl
subject
proteom
analysi
use
surfaceenhanc
laser
desorptionion
timeofflight
selditof
mass
spectroscopi
discrimin
proteom
biomark
profil
extract
appli
mass
restrict
analysi
preeclampsia
proteom
biomark
ppb
score
develop
base
presenc
absenc
four
discriminatori
protein
peak
individu
csf
seldi
trace
ingel
tryptic
digest
western
blot
analysi
onchip
immunoassay
elisa
spectral
analysi
use
identifi
biomark
compos
ppb
score
ppb
score
distinguish
patient
clinic
diagnosi
sever
preeclampsia
spe
mild
preeclampsia
mpe
normotens
control
ppb
score
unaffect
pariti
magnesium
seizur
prophylaxi
csf
leukocyt
count
total
protein
content
proteom
identif
techniqu
match
discriminatori
protein
peak
alpha
betahemoglobin
chain
elisa
confirm
women
diagnos
clinic
spe
significantli
higher
csf
hemoglobin
concentr
women
mpe
crl
thu
proteom
analysi
csf
accur
distinguish
spe
mpe
normotens
control
patient
spe
nanomolar
amount
free
hemoglobin
csf
studi
need
confirm
observ
determin
physiolog
implic
protein
known
involv
program
cell
death
cell
chang
invas
ie
abil
cell
invad
colon
new
area
process
physiolog
establish
growth
placenta
uteru
first
trimest
invas
also
patholog
case
cancer
aberr
express
development
regul
gene
placent
develop
could
affect
fetal
growth
contribut
preeclampsia
studi
design
determin
express
placent
tissu
control
preeclampt
pregnanc
determin
effect
express
trophoblast
cell
migrat
invas
ajayi
et
al
higher
express
detect
placent
tissu
collect
patient
earlyonset
preeclampsia
compar
gestat
agematch
control
sampl
higher
express
associ
earlyonset
preeclampsia
may
affect
trophoblast
cell
migrat
invas
work
first
link
high
level
thirdtrimest
placent
tissu
sever
preeclampsia
though
preliminari
find
may
one
day
lead
develop
blood
test
track
level
identifi
women
risk
preeclampsia
although
initi
result
realli
encourag
earli
say
definit
biomark
preeclampsia
greater
amount
indic
greater
placent
distress
diseas
sever
develop
blood
test
detect
level
may
possibl
serv
earli
warn
system
placent
condit
chang
hope
predict
test
would
allow
physician
manag
preeclampsia
nonemerg
basi
less
threaten
mother
fetu
possibl
devis
therapi
stop
process
prevent
altogeth
matern
endotheli
dysfunct
mediat
excess
placentaderiv
solubl
vegf
receptor
solubl
fmslike
tyrosin
kinas
emerg
promin
compon
diseas
pathogenesi
increas
level
free
measur
immunoassay
serum
urin
sampl
preeclampsia
patient
buhimschi
et
al
howev
unknown
reason
subset
preeclampsia
patient
go
experi
sever
preeclampsia
group
dramat
escal
symptom
character
sudden
massiv
rise
blood
pressur
lead
onset
seizur
well
develop
fetal
growth
restrict
hellp
hemolysi
elev
liver
enzym
low
platelet
syndrom
indic
mother
liver
bloodclot
system
function
properli
health
mother
infant
seriou
danger
investig
hellp
led
search
anoth
factor
act
jointli
induc
vascular
damag
escal
diseas
sever
form
novel
placentaderiv
solubl
coreceptor
endoglin
seng
elev
sera
preeclampt
individu
correl
diseas
sever
fall
deliveri
venkatesha
et
al
seng
inhibit
format
capillari
tube
vitro
induc
vascular
permeabl
hypertens
vivo
effect
pregnant
rat
amplifi
coadministr
lead
sever
preeclampsia
includ
hellp
hemolysi
elev
liver
enzym
low
platelet
syndrom
restrict
fetal
growth
seng
impair
bind
receptor
downstream
signal
includ
effect
activ
eno
vasodil
suggest
seng
lead
dysregul
signal
vasculatur
result
suggest
seng
may
act
concert
induc
sever
preeclampsia
consid
biomark
condit
import
diagnost
therapeut
implic
manag
diseas
placent
rna
analyz
matern
plasma
permit
rapid
screen
novel
biomark
includ
marker
access
antibodybas
assay
includ
transcript
factor
noncod
rna
epigenet
featur
well
gene
function
genet
link
preeclampsia
review
gene
placent
express
human
symatla
comparison
proven
qualifi
larg
set
rna
biomark
target
use
matern
plasma
smet
et
al
biomark
qualifi
novel
rna
biomark
presymptomat
detect
first
trimest
pregnancyassoci
diseas
placent
origin
andor
dysfunct
pregnancyinduc
hypertens
without
proteinuria
preeclampsia
intrauterin
growth
restrict
estim
preterm
labor
complic
pregnanc
common
caus
neonat
morbid
mortal
worldwid
statist
reflect
may
mani
million
preterm
birth
annual
figur
predict
increas
unit
state
estim
million
spent
preterm
hospit
subsequ
shown
unnecessari
hospit
tax
mother
health
healthcar
resourc
current
rapid
accur
test
posit
predict
preterm
labor
profil
specif
protein
amniot
fluid
inflamm
research
yale
school
medicin
new
ct
quickli
accur
detect
potenti
danger
infect
pregnant
women
also
predict
possibl
prematur
birth
mass
restrict
mr
score
specif
proteom
profil
use
studi
presenc
biomark
indic
inflamm
amniot
fluid
establish
min
test
much
faster
current
method
test
microbiolog
cultur
biomark
present
pregnanc
uncompl
protein
small
sampl
amniot
fluid
test
find
link
amniot
fluid
glucos
valu
white
blood
cell
count
outcom
fetu
mr
sore
three
four
highli
predict
advers
pregnanc
outcom
presenc
two
biomark
inflamm
indic
median
time
deliveri
day
biomark
inflamm
present
deliveri
time
occur
within
hour
studi
test
treatment
possibl
result
test
use
provid
rapid
treatment
mother
babi
metabolom
inc
identifi
specif
metabolit
biomark
amniot
fluid
metabolom
enabl
classif
patient
risk
preterm
deliveri
women
present
week
pregnanc
prematur
labor
three
outcom
fals
labor
normal
fullterm
pregnanc
prematur
birth
bacteri
infect
lead
inflamm
stereotyp
pattern
metabolit
identifi
differ
group
observ
enabl
identif
metabol
pathway
alter
preterm
labor
third
blind
studi
refin
algorithm
order
improv
precis
plan
well
studi
urin
plasma
perkinelm
collabor
univers
leicest
uk
work
discoveri
biomark
predict
preterm
birth
oxid
stress
may
contribut
develop
complic
pregnanc
antioxid
activ
matern
umbil
cord
blood
may
indic
oxygen
radic
activ
variou
paramet
oxid
stress
measur
pregnanc
hypertens
preeclampsia
insulindepend
diabet
mellitu
gestat
diabet
mellitu
oligohydramnio
abruptio
placenta
well
healthi
control
group
result
studi
suggest
oxid
stress
subsequ
lipid
peroxid
accompani
complic
hypertens
preeclampsia
diabet
mellitu
pregnanc
matern
erythrocyt
gst
activ
seem
sensit
indic
oxid
stress
deliveri
enzym
use
cord
blood
biomark
oxid
stress
upon
sudden
increas
oxygen
deliveri
multiparamet
biomark
also
use
monitor
effici
antioxid
supplement
complic
pregnant
women
premenstru
dysphor
disord
pmdd
sever
form
premenstru
syndrom
affect
menstruat
women
symptom
disord
includ
mark
depress
anxieti
tension
irrit
moodi
consid
mood
disord
women
affect
pmdd
significantli
reduc
qualiti
life
trigger
reproduct
hormon
caus
pmdd
unknown
current
treatment
option
rang
nutrit
supplement
prescript
medicin
pmdd
afflict
signific
portion
femal
popul
yet
littl
known
definit
cure
menopaus
metabolon
scientist
compar
sampl
women
pmdd
sampl
normal
healthi
women
control
hormon
condit
metabolon
analyz
data
identifi
biomark
indic
metabol
differ
two
group
result
studi
could
potenti
lead
effect
treatment
disord
metabolon
technolog
identifi
biomark
use
develop
new
treatment
disord
symptom
endometriosi
pain
chronic
diseas
occur
endometrium
tissu
line
uteru
found
outsid
uteru
usual
abdomen
ovari
fallopian
tube
ligament
support
uteru
area
vagina
rectum
outer
surfac
uteru
line
pelvic
caviti
affect
million
femal
north
america
million
worldwid
misplac
tissu
develop
growth
lesion
respond
menstrual
cycl
way
tissu
uterin
line
month
tissu
build
break
shed
result
intern
bleed
breakdown
blood
tissu
lesion
inflamm
caus
pain
infertil
scar
tissu
format
adhes
bowel
problem
diagnosi
endometriosi
surgic
laparoscopi
invas
costli
associ
potenti
complic
noninvas
test
diagnosi
endometriosi
focu
use
laparoscopi
women
highli
suspect
endometriosi
consider
effort
made
discov
biomark
endometriosi
noninvas
diagnosi
one
studi
use
dna
microarray
look
biomark
endometriosi
peripher
blood
lymphocyt
premenopaus
women
without
endometriosi
undergo
gynecolog
procedur
flore
et
al
gene
select
program
identifi
two
gene
differenti
express
peripher
blood
lymphocyt
sampl
endometriosi
patient
may
provid
import
clue
regard
pathogenesi
diseas
moreov
could
consid
potenti
target
noninvas
diagnost
assay
endometriosi
need
valid
larger
popul
provid
promis
serum
biomark
nonsurg
predict
endometriosi
othman
et
al
although
biomark
investig
show
good
specif
none
high
sensit
multicent
studi
larger
number
patient
requir
identifi
use
biomark
discoveri
fetal
mrna
transcript
matern
circul
hold
great
promis
noninvas
prenat
diagnosi
identifi
potenti
fetal
biomark
rna
isol
peripher
umbil
blood
hybrid
gene
express
array
maron
et
al
gene
express
pair
student
ttest
pathway
analys
perform
identifi
fetal
biomark
includ
development
gene
sensori
percept
gene
gene
involv
neonat
physiolog
transcript
predominantli
express
restrict
fetu
embryo
neonat
realtim
rtpcr
amplif
confirm
presenc
specif
gene
transcript
snp
analysi
demonstr
presenc
fetal
transcript
matern
antepartum
blood
comparison
whole
blood
plasma
sampl
pregnant
woman
suggest
placent
gene
easili
detect
plasma
find
show
fetal
placent
mrna
circul
blood
pregnant
women
transcript
analysi
matern
whole
blood
identifi
uniqu
set
biolog
divers
fetal
biomark
multitud
clinic
applic
syndrom
genet
disord
caus
inherit
three
copi
chromosom
common
congenit
disord
impair
mental
function
larg
percentag
individu
develop
alzheim
diseas
fifth
decad
life
controversi
best
approach
screen
syndrom
compet
claim
advoc
differ
screen
approach
made
difficult
health
planner
clinician
pregnant
women
reach
balanc
decis
offer
chosen
serum
test
use
screen
syndrom
includ
chorion
gonadotrophin
hcg
alphafetoprotein
afp
unconjug
oestriol
serum
pregnanc
associ
plasma
proteina
pappa
dimer
inhibin
novel
serum
marker
biolog
properti
similar
pappa
serum
urin
ultrasound
screen
studi
suruss
advanc
knowledg
efficaci
safeti
antenat
screen
fetal
syndrom
place
choic
firmer
platform
evid
wald
et
al
best
perform
integr
test
compris
ultrasound
measur
fetal
nuchal
transluc
assay
pappa
week
combin
quadrupl
test
serum
unconjug
oestriol
hcg
inhibin
second
trimest
week
twostep
packag
falseposit
rate
best
first
trimest
screen
packag
combin
nuchal
transluc
scan
serumfre
pregnancyassoci
plasma
protein
falseposit
rate
second
trimest
quadrupl
test
alon
falseposit
rate
quadrupl
marker
prenat
screen
test
alfigen
inc
blood
screen
test
done
second
trimest
pregnanc
week
help
detect
increas
risk
syndrom
trisomi
neural
tube
defect
abdomin
wall
defect
occasion
test
may
also
detect
risk
chromosom
abnorm
test
measur
concentr
four
biochem
substanc
produc
fetu
placenta
afp
hcg
dimer
inhibin
test
valu
togeth
matern
age
enter
mathemat
formula
determin
risk
variou
abnorm
ad
fourth
marker
prenat
screen
test
detect
rate
elev
risk
syndrom
increas
duchenn
becker
muscular
dystrophi
dmd
bmd
share
clinic
symptom
like
muscl
weak
wast
differ
clinic
present
sever
immunohistochemistri
use
antibodi
dystrophin
patholog
basi
diagnosi
dmd
bmd
sarcolemma
dmd
muscl
neg
bmd
muscl
gener
show
variabl
label
translat
partial
function
dystrophin
local
sarcolemma
case
differenti
possibl
instanc
immunolabel
antibodi
neuron
form
nitric
oxid
synthas
nno
use
suspect
dystrophinopathi
mutat
hotspot
rod
domain
help
direct
molecular
analysi
torelli
et
al
nno
local
sarcolemma
matur
muscl
fiber
via
sever
compon
dystrophinassoci
protein
complex
includ
dystrophin
sarcolemm
nno
lost
dystrophin
level
low
absent
delet
critic
region
rod
domain
gene
express
profil
hind
limb
muscl
mous
model
muscular
dystrophi
shown
clearli
discrimin
sever
affect
mildli
nonaffect
mous
model
turk
et
al
dystrophindefici
sarcoglycandefici
profil
remark
similar
share
inflammatori
structur
remodel
process
process
also
ongo
dysferlindefici
anim
although
lower
level
agreement
later
age
onset
muscular
dystrophi
inflammatori
protein
upregul
model
studi
identifi
biomark
gene
express
correl
sever
diseas
compar
studi
import
step
toward
develop
express
profilingbas
diagnost
approach
muscular
dystrophi
human
phenylketonuria
pku
genet
diseas
affect
live
birth
condit
phenylalanin
hydroxylas
pah
defici
inherit
autosom
recess
trait
associ
hyperphenylalaninemia
phenotyp
highli
variabl
neurolog
abnorm
phenylketonuria
includ
tremor
clumsi
epilepsi
spastic
paraparesi
intellectu
impair
screen
pku
introduc
uk
year
ago
prove
success
prevent
sever
mental
retard
genotypebas
predict
biochem
phenotyp
feasibl
major
newborn
hyperphenylalaninemia
may
use
refin
diagnosi
anticip
dietari
requir
method
current
use
screen
pku
includ
spectrophotometri
fluorometri
immunoassay
tandem
mass
spectrometri
electrospray
ioniz
recent
develop
tandem
mass
spectrometri
made
technic
possibl
screen
sever
inborn
error
metabol
singl
analyt
step
neolynx
screen
applicationmanag
micromass
inc
indic
quantit
measur
phenylalanin
tyrosin
neonat
blood
sampl
tandem
mass
spectrometri
exclus
quattro
microquattro
lc
mass
spectromet
micromass
addit
measur
tyrosin
use
adjunct
measur
phenylalanin
reduc
number
falseposit
result
micromass
neolynx
screen
applicationmanag
although
sever
therapi
avail
develop
lysosom
storag
disord
lsd
assess
therapeut
efficaci
limit
lack
biomark
assess
diseas
progress
sever
particularli
true
rare
diseas
lsd
sinc
natur
histori
data
human
popul
often
lack
gene
express
analysi
acid
sphingomyelinasedefici
mous
model
asmko
type
b
diseas
npd
use
identifi
novel
serum
biomark
dhami
et
al
microarray
realtim
pcr
analys
use
compar
mrna
express
asmko
normal
mice
two
import
site
patholog
lung
brain
data
identifi
valid
sever
potenti
biomark
cytokin
markedli
elev
asmko
mous
serum
follow
enzym
replac
therapi
ert
reduc
normal
level
total
iron
level
similarli
elev
asmko
mice
reflect
elev
ferritin
light
chain
transcript
decreas
normal
ert
serum
growth
hormon
level
also
elev
asmko
mice
reduc
normal
braindirect
gene
therapi
ert
studi
illustr
valu
gene
express
analysi
identif
biomark
provid
new
insight
pathobiolog
npd
mucopolysaccharidos
mp
anoth
group
lsd
present
broad
multisystem
diseas
continu
rang
phenotyp
current
object
biomark
mp
diseas
clearli
reflect
diseas
sever
therapeut
respons
format
heparin
cofactor
iithrombin
hciit
complex
wellknown
serin
proteas
inhibitor
serpin
serin
proteas
complex
identifi
inform
biomark
mp
use
proteom
studi
murin
mp
model
randal
et
al
hciit
complex
also
elev
plasma
mp
patient
degre
hciit
complex
format
appear
correl
diseas
sever
respons
therapi
addit
role
biomark
discoveri
increas
proteas
complex
format
provid
valuabl
insight
possibl
pathophysiolog
mechan
mp
gaucher
diseas
common
lsd
gene
defect
lead
defici
decreas
activ
glucocerebrosidas
follow
accumul
glucosylceramid
frequent
manifest
hepatosplenomegali
anemia
skelet
hematolog
abnorm
recent
use
enzym
replac
therapi
inifuceras
seem
elimin
need
bone
marrow
transplant
favor
effect
symptom
outcom
develop
gene
therapi
reintroduct
miss
dna
sequenc
offer
possibl
cure
diseas
biochem
marker
secret
gaucher
cell
numer
none
identifi
date
offer
expect
qualiti
biomark
chitotriosidas
chemokin
use
marker
follow
enzym
replac
therapi
identif
new
biomark
near
futur
enabl
clearer
understand
pathophysiolog
complex
diseas
involv
numer
cell
process
fucosidosi
anoth
lsd
autosom
recess
disord
result
defici
encod
gene
lead
failur
catabol
glycoprotein
glycosphingolipid
result
accumul
rang
fucooligosaccharid
sphingolipid
tissu
includ
brain
liver
sever
affect
patient
present
within
first
year
life
mental
retard
growth
retard
abnorm
variou
organ
diagnost
procedur
either
invas
impract
pcr
use
mutat
known
practic
test
detect
mass
spectrometri
elev
oligosaccharid
biomark
urin
prenat
diagnosi
avail
mani
lsd
use
chorion
villu
sampl
amniocyt
diagnos
problemat
sampl
transport
cultur
requir
prior
analysi
possibl
identifi
use
biomark
diagnosi
lsd
amniot
fluid
amniot
fluid
sampl
control
lsd
affect
pregnanc
analyz
protein
marker
saposin
c
elisa
oligosaccharid
lipid
metabolit
biomark
electrospray
ionizationtandem
mass
spectrometri
ramsay
et
al
lsd
sampl
includ
aspartylglucosaminuria
galactosialidosi
gaucher
diseas
gangliosidosi
mucopolysaccharidosi
type
ii
iiic
iva
vi
vii
mucolipidosi
type
ii
multipl
sulfatas
defici
sialidosi
type
ii
disord
produc
uniqu
signatur
metabol
profil
protein
oligosaccharid
glycolipid
biomark
metabolit
elev
directli
relat
disord
other
appear
unrel
primari
defect
mani
lsd
clearli
distinguish
control
popul
second
trimest
one
case
first
trimest
sampl
gangliosidosi
mucopolysaccharidosi
type
vii
display
correl
gestat
age
amount
store
metabolit
preliminari
result
provid
proof
princip
use
biomark
contain
amniot
fluid
clinic
test
frequent
lsd
caus
hydrop
fetali
accord
unesco
preserv
parsi
zoroastrian
project
parsi
popul
india
live
beyond
age
compar
nation
http
wwwunescoparzorcom
better
understand
genet
caus
longev
could
major
impact
indian
govern
healthcar
budget
drug
compani
market
effort
affymetrix
sign
agreement
avesthagen
ltd
bangalor
india
wherebi
affymetrix
microarray
technolog
use
avestagenom
explor
genet
basi
longev
creat
genet
genealog
medic
databas
popul
use
affymetrix
technolog
enabl
research
correl
gene
longev
well
neurodegen
condit
breast
cancer
diabet
complex
diseas
affect
parsi
commun
parsi
commun
select
longev
rel
genet
homogen
popul
project
take
system
biolog
approach
encompass
genotyp
also
express
profil
transcriptom
genotyp
phase
project
began
consist
sampl
first
year
middl
team
perform
express
profil
transcript
map
experi
across
subset
sampl
project
expect
complet
genet
inform
avestagenom
collect
follow
inform
consent
data
confidenti
maintain
accord
indian
council
medic
research
guidelin
telomer
tandemrep
hexam
end
mammalian
chromosom
telomer
shorten
associ
cellular
senesc
mean
telomer
length
emerg
replic
clock
within
popul
cell
tissu
organ
build
vitro
consequ
biomark
biolog
age
vivo
chronolog
age
per
se
parallel
biolog
age
yet
accur
reliabl
biomark
lack
distinguish
question
remain
whether
telomer
dynam
determin
mere
predictor
human
biolog
age
chronolog
age
although
sever
report
suggest
link
telomer
attrit
age
phenotyp
disord
refer
valu
complet
set
determin
miss
age
telomer
attrit
associ
higher
mortal
due
infect
cardiovascular
diseas
increas
telomer
eros
peripher
blood
leukocyt
associ
atherosclerosi
hypercholesterolemia
hypertens
diabet
mellitu
longer
telomer
associ
slower
age
biomark
age
identifi
skin
eshaghian
et
al
mitochondri
dna
mtdna
delet
mutat
observ
skin
sampl
remov
patient
nonmelanoma
skin
cancer
panel
mtdna
delet
found
tumorfre
skin
adjac
tumor
tumor
tumor
sampl
like
fulllength
mtdna
point
mutat
rather
signific
delet
mitochondri
dna
mutat
tumorfre
skin
correl
age
process
newli
identifi
delet
mutat
go
mitomap
databas
known
human
mitochondri
genom
chang
unravel
molecular
clue
age
cell
function
differ
young
cell
requir
molecular
marker
track
interest
see
mtdna
mutat
report
marker
age
skin
found
tissu
well
found
tissu
expos
ultraviolet
light
theori
cellular
age
center
mitochondria
decreas
energet
capac
result
mtdna
mutat
studi
support
use
mtdna
mutat
biomark
photoag
skin
newli
identifi
biomark
provid
anoth
tool
studi
mitochondri
damag
contribut
age
cancer
screen
compound
condit
system
wide
function
structur
chang
caus
age
process
encourag
implement
new
bioinformat
search
strategi
marker
age
combinatori
biomark
particularli
favor
quantifi
process
multipl
level
biolog
organ
overcom
otherwis
limit
abil
access
heterogen
popul
even
challeng
ration
approach
develop
system
biolog
model
describ
molecular
pathway
key
network
mechanist
relat
age
revers
engin
model
indic
critic
diagnost
compon
potenti
biomark
also
abl
predict
progress
age
comput
simul
kriet
prolong
calori
restrict
cr
increas
life
span
rodent
random
control
trial
call
comprehens
assess
longterm
effect
reduc
intak
energi
caleri
conduct
determin
prolong
cr
affect
biomark
longev
marker
oxid
stress
reduc
metabol
rate
beyond
expect
reduc
metabol
mass
human
heilbron
et
al
find
suggest
two
biomark
longev
fast
insulin
level
bodi
temperatur
decreas
prolong
cr
human
support
theori
metabol
rate
reduc
beyond
level
expect
reduc
metabol
bodi
mass
subject
cr
less
oxid
damag
dna
thought
marker
age
biochem
cellular
level
inflammatori
bowel
diseas
ibd
spectrum
disord
affect
gastrointestin
tract
two
major
entiti
crohn
diseas
ulcer
coliti
ibd
endur
diseas
involv
mostli
young
peopl
symptom
bloodi
diarrhea
abdomin
cramp
sever
antibodi
associ
ibd
two
comprehens
studi
autoantibodi
neutrophil
atyp
perinuclear
antineutrophil
cytoplasm
antibodi
antisaccharomyc
cerevisia
antibodi
asca
antibodi
use
diagnos
ibd
differenti
crohn
diseas
ulcer
coliti
indetermin
coliti
monitor
diseas
defin
clinic
phenotyp
predict
respons
therapi
subclin
biomark
bossuyt
pancreat
antibodi
describ
patient
crohn
diseas
antigen
elucid
antibodi
detect
indirect
immunofluoresc
evid
number
magnitud
immun
respons
differ
microbi
antigen
outer
membran
porin
c
asca
given
patient
associ
sever
diseas
cours
ie
greater
number
respons
greater
magnitud
sever
diseas
cours
interest
antimicrobi
antiglycan
antibodi
recent
increas
shown
act
surrog
marker
complic
aggress
diseas
correl
serum
biomark
genotyp
clinic
phenotyp
would
enhanc
understand
pathophysiolog
ibd
lead
new
tool
diagnosi
stratif
patient
clinic
trial
biomark
help
priorit
examin
includ
endoscopi
andor
decis
start
intensifi
treatment
ibd
crp
mani
advantag
short
halflif
make
particularli
good
biomark
detect
followup
diseas
activ
crohn
diseas
contrast
ulcer
coliti
except
sever
coliti
modesttoabs
crp
respons
despit
activ
inflamm
stool
easi
access
ibd
patient
fecal
biomark
hold
specif
promis
recent
studi
even
claim
superior
fecal
biomark
serum
marker
number
neutrophilderiv
protein
shed
stool
studi
calprotectin
lactoferrin
probabl
promis
given
abund
granulocyt
stabil
resist
degrad
vermeir
et
al
although
calprotectin
lactoferrin
sensit
marker
detect
inflamm
gastrointestin
tract
specif
ibd
increas
level
also
found
neoplasia
nsaid
abus
infect
polyp
children
abdomin
symptom
diarrhea
posit
test
calprotectin
lactoferrin
may
priorit
endoscopi
erectil
dysfunct
ed
highli
preval
function
disord
incid
increas
advanc
age
populationbas
studi
estim
preval
nearli
male
popul
age
across
racial
socioeconom
group
multipl
risk
factor
biomark
ed
current
serum
testosteron
consid
reliabl
biomark
establish
presenc
ed
due
hypogonad
ed
commonli
seen
men
variou
compon
metabol
syndrom
consid
risk
marker
metabol
syndrom
associ
condit
diabet
cardiovascular
diseas
demograph
studi
consist
demonstr
risk
factor
ed
gener
mirror
risk
factor
also
predict
coronari
vascular
diseas
secondari
endotheli
dysfunct
vascular
tree
risk
factor
includ
obes
hyperlipidemia
hypertens
diabet
mellitu
smoke
sedentari
lifestyl
among
other
clinic
studi
comorbid
much
higher
ed
popul
report
gener
popul
variou
studi
support
concept
ed
marker
cardiovascular
diseas
furthermor
endotheli
dysfunct
biomark
vascular
diseas
flowmedi
reflex
brachial
arteri
dilat
describ
diagnost
test
endotheli
dysfunct
high
correl
erectil
dysfunct
commonli
done
difficult
standard
costli
time
consum
therefor
accept
screen
test
procedur
coronari
endotheli
dysfunct
ced
preced
atherosclerosi
associ
cardiovascular
event
ced
erectil
dysfunct
ed
partli
mediat
impair
nitric
oxid
pathway
although
ed
associ
establish
coronari
atherosclerosi
relationship
ced
unknown
studi
investig
associ
ced
ed
men
earli
coronari
atherosclerosi
well
role
endogen
nitric
oxid
synthas
inhibitor
asymmetr
dimethylarginin
adma
shown
independ
biomark
cardiovascular
diseas
elesb
et
al
result
show
ced
independ
associ
ed
plasma
adma
concentr
men
earli
coronari
atherosclerosi
support
role
endothelium
system
vascular
diseas
role
adma
system
manifest
endotheli
dysfunct
daili
sildenafil
week
amelior
endotheli
function
patient
ed
assess
reduct
level
biomark
endotheli
function
nitric
oxid
cyclic
guanosin
monophosph
ang
et
al
clinic
implic
find
warrant
investig
avail
simpl
costeffect
biomark
identifi
men
risk
would
allow
earlier
treatment
earlier
evalu
intervent
could
potenti
significantli
improv
cardiovascular
health
prevent
postpon
potenti
seriou
lifethreaten
event
heat
stroke
also
term
sun
stroke
character
hyperpyrexia
core
bodi
temperatur
greater
neurolog
dysfunct
earli
detect
manag
essenti
improv
chanc
recoveri
surviv
valid
biomark
earli
detect
heat
stroke
studi
progress
identifi
heatshock
protein
hsp
concentr
shown
higher
serum
runner
symptom
heat
ill
nonil
runner
function
core
temperatur
attain
rather
rate
heat
storag
amorim
et
al
measur
antibodi
hsp
may
use
assess
individu
respond
abnorm
heat
stress
within
live
work
environ
may
use
biomark
evalu
suscept
heatinduc
diseas
although
chang
nervou
system
neuropath
pain
difficult
identifi
biomark
blood
peripher
tissu
evid
cn
involv
neuropath
pain
movement
disord
patient
complex
region
pain
syndrom
crp
elev
cerebrospin
fluid
csf
level
report
crp
patient
without
movement
disord
studi
fail
replic
find
use
proteom
technolog
studi
protein
involv
pathogenesi
nerv
injuri
neuropath
pain
might
enabl
better
understand
pathophysiolog
signal
pathway
impair
facilit
discoveri
specif
biomark
valid
histolog
biomark
provid
foundat
research
advanc
new
clinic
trial
design
allow
better
discrimin
benefici
treatment
neuropath
pain
fibromyalgia
fm
chronic
widespread
pain
condit
thought
aris
augment
central
neural
activ
glutam
glu
excitatori
neurotransmitt
function
painprocess
pathway
studi
carri
investig
relationship
chang
level
glu
within
insula
chang
multipl
pain
domain
patient
fm
harri
et
al
proton
magnet
reson
spectroscopi
hmr
fmri
examin
conduct
nonpharmacolog
intervent
reduc
pain
hmr
anterior
posterior
insular
region
examin
separ
use
singlevoxel
spectroscopi
level
glu
metabolit
estim
rel
level
creatin
cr
eg
glucr
ratio
fmri
pain
pressur
appli
thumbnail
elicit
neuron
activ
experiment
pressureevok
pain
threshold
clinic
pain
rate
also
assess
prior
imag
session
experiment
pain
clinic
pain
reduc
follow
treatment
chang
pre
posttreat
glucr
neg
correl
chang
experiment
pain
threshold
posit
correl
chang
clinic
pain
conclud
chang
glu
level
within
insula
associ
chang
multipl
pain
domain
patient
fm
thu
hmr
data
may
serv
use
biomark
surrog
end
point
clinic
trial
fm
need
predict
biomark
test
novel
experiment
medicin
function
gastrointestin
disord
viscer
pain
model
larg
coeffici
variat
sensat
end
point
human
studi
preclud
definit
conclus
gono
go
decis
dose
select
phase
iib
iii
studi
unless
larg
number
patient
evalu
phase
iia
pharmacodynam
studi
render
pharmacolog
studi
ambiti
unachiev
time
fashion
moreov
result
test
clinic
trial
interpret
greater
knowledg
drug
pharmacokinet
includ
influenc
cyp
metabol
potenti
drug
interact
thu
import
identifi
valid
biomark
viscer
pain
assess
treatment
respons
pharmacodynam
studi
present
clear
evid
effect
biomark
viscer
pain
pharmacolog
agent
avail
test
date
abl
demonstr
modest
chang
sensori
end
point
except
singl
studi
highdos
fentani
octreotid
show
magnitud
chang
would
demonstr
reason
number
particip
least
howev
studi
fentanyl
record
fact
particip
identifi
fentanyl
particip
report
alter
perform
moreov
conceiv
local
irrit
effect
octreotid
site
inject
may
unblind
studi
caus
compet
somat
pain
interf
apprais
viscer
sensat
rectal
sensit
brainimag
studi
seem
labori
impract
use
pharmacodynam
model
still
unclear
whether
foci
activ
brain
specif
irrit
bowel
syndrom
ib
inde
studi
contrast
limin
sublimin
supralimin
stimuli
rectum
acoust
control
stimulu
show
activ
higher
emot
center
may
close
reflect
psycholog
state
true
center
associ
function
gastrointestin
diseas
andresen
camilleri
unclear
whether
activ
brain
center
provid
true
reflect
biomark
ib
viscer
pain
assess
respons
chronic
rhinosinus
therapi
difficult
ct
scan
use
repeatedli
therefor
method
symptom
score
endoscopi
employ
instead
nasal
consid
potenti
biomark
assess
effect
treatment
prospect
random
trial
nasal
measur
conduct
patient
chronic
rhinosinus
fail
initi
medic
therapi
douch
nasal
corticosteroid
abnorm
ct
scan
ragab
et
al
patient
treat
either
medic
surgic
followup
month
still
take
nasal
corticosteroid
nasal
measur
initi
month
along
symptom
score
endoscopi
polyp
grade
saccharin
clearanc
time
result
show
initi
absolut
nasal
level
correl
invers
ct
scan
chang
percentag
rise
nasal
seen
medic
surgic
treatment
correl
chang
symptom
score
saccharin
clearanc
time
endoscop
chang
polyp
grade
surgic
score
month
well
month
nasal
easili
measur
provid
valuabl
noninvas
object
measur
respons
chronic
rhinosinus
therapi
topic
nasal
corticosteroid
may
need
reduc
contribut
nasal
eno
allow
eman
sinus
measur
current
expens
chemiluminesc
analyz
would
limit
applic
method
clinic
practic
biomark
found
one
diseas
evalu
requir
correl
clinic
manifest
exampl
list
tabl
modern
epidemiolog
suggest
potenti
interact
associ
diet
lifestyl
genet
risk
mani
chronic
diseas
mani
epidemiolog
studi
attempt
consid
assess
dietari
intak
alongsid
genet
measur
variabl
interest
howev
given
multifactori
complex
dietari
exposur
dietari
intak
assess
method
associ
measur
error
affect
dietari
estim
may
obscur
diseas
risk
associ
reason
dietari
biomark
measur
biolog
specimen
increasingli
use
addit
substitut
estim
dietari
intak
nutrient
statu
genet
variat
may
influenc
dietari
intak
nutrient
metabol
may
affect
util
dietari
biomark
properli
reflect
dietari
exposur
although
mani
function
dietari
biomark
util
appropri
inform
better
understand
interact
diet
gene
potenti
determin
factor
valid
applic
interpret
dietari
biomark
necessari
import
biomark
appli
nutrit
epidemiolog
address
associ
question
limit
jenab
et
al
still
need
identifi
new
dietari
biomark
nutrit
metabonom
use
analyt
method
assess
metabol
profil
measur
dietari
exposur
indic
dietari
pattern
dietari
chang
effect
dietari
intervent
futur
studi
integr
highqual
dietari
intak
inform
measur
dietari
biomark
metabol
profil
specif
dietari
pattern
genet
novel
statist
method
provid
import
new
insight
genedietlifestylediseas
risk
associ
human
individu
differ
respons
diet
nutrit
take
account
differ
genet
metabol
need
avail
diagnost
biomark
diseas
may
appropri
adequ
distinguish
nutrit
statu
human
form
basi
recommend
appropri
diet
optim
metabol
health
metabol
profil
use
metabolom
requir
purpos
need
measur
metabolit
assess
human
metabol
prior
onset
diseas
current
use
singl
biomark
indic
diseas
replac
comprehens
profil
individu
metabolit
link
understand
health
human
metabol
determin
metabolom
industri
academ
initi
current
develop
analyt
bioinformat
technolog
need
assembl
quantit
refer
databas
metabolit
metabol
analog
human
genom
place
dietet
profession
abl
assess
current
health
statu
individu
predict
health
trajectori
facilit
integr
metabol
genet
dietari
variabl
affect
health
lead
person
nutrit
counsel
howev
pauciti
good
studi
nutrit
biomark
low
serum
concentr
vitamin
selenium
biomark
predict
subsequ
disabl
activ
daili
life
older
women
live
commun
bartali
et
al
one
key
factor
consid
develop
strategi
aim
prevent
delay
disabl
process
branchedchain
amino
acid
bcaa
synthes
bodi
human
crucial
protein
neurotransmitt
synthesi
protein
anabol
role
bcaa
seem
mediat
import
role
promot
translat
process
possibl
act
transcript
level
also
inhibit
protein
degrad
leucin
may
play
critic
role
signal
pathway
supplement
bcaa
spare
lean
bodi
mass
weight
loss
promot
wound
heal
may
decreas
muscl
wast
age
may
benefici
effect
renal
liver
diseas
bcaa
supplement
extens
use
athlet
field
assumpt
improv
perform
muscl
mass
measur
serum
bcaa
limit
clinic
util
beyond
control
set
level
affect
varieti
clinic
state
optim
level
scenario
complet
elucid
diet
hormon
stress
age
renal
liver
dysfunct
affect
bcaa
level
understand
biolog
effect
bcaa
may
help
develop
biomark
bcaa
statu
calor
restrict
associ
decreas
level
oxid
stress
reactiv
oxygen
speci
ro
gener
predominantli
mitochondria
attenu
decreas
calor
intak
skrha
hand
antioxid
mechan
frequent
acceler
increas
gene
express
activ
antioxid
enzym
superoxid
dismutas
catalas
glutathion
peroxidas
paraoxonas
etc
measur
biomark
oxid
stress
calor
restrict
therefor
import
experiment
well
clinic
studi
estim
ro
tissu
fluid
typic
perform
measur
oxid
product
ie
malondialdehyd
nitrotyrosin
biomark
antioxid
system
enzym
glutathion
alphatocopherol
ascorb
acid
ubichinon
etc
malnutrit
gener
term
medic
condit
caus
improp
inadequ
diet
nutrit
manifest
may
subclin
malnutrit
common
infant
third
world
major
caus
infant
mortal
nucleotid
intak
nutrit
recoveri
notabl
effect
igfi
igfbind
hormon
biomark
et
al
outcom
could
stimul
catchup
growth
sever
malnourish
infant
toddler
nutrit
recoveri
period
malnutrit
found
even
among
elderli
develop
countri
level
serum
lipid
influenc
malnutrit
inflamm
total
cholesterol
hdl
ldl
consid
novel
biomark
malnutrit
inflamm
geriatr
patient
hrnciarikova
et
al
close
relat
also
demonstr
serum
lipid
prealbumin
healthi
elderli
subject
plasma
transthyretin
alpha
glycoprotein
could
help
identifi
elderli
subject
higher
risk
death
carrier
et
al
scientist
research
centr
lausann
switzerland
employ
proteom
address
question
nutrit
health
believ
food
drink
affect
individu
consum
differ
food
may
welltoler
one
individu
caus
caus
violent
gastric
discomfort
anoth
food
prefer
may
relat
biomark
worthwhil
investig
gene
activ
specif
food
enhanc
health
well
certain
individu
predispos
other
condit
like
obes
diabet
protein
marker
indic
predisposit
identifi
diseas
symptom
aris
dietari
approach
could
devis
health
promot
diseas
prevent
includ
genom
proteom
approach
consum
research
impart
health
well
dimens
accur
address
individu
differ
term
respons
diet
food
prefer
longterm
deliver
omic
driven
food
research
person
nutrit
proteom
adapt
appli
context
nutrit
health
potenti
deliv
biomark
health
comfort
reveal
earli
indic
diseas
disposit
assist
differenti
dietari
respond
nonrespond
last
least
discov
bioactiv
benefici
food
compon
kussmann
affolt
interact
play
import
role
human
diseas
studi
systemat
gene
environ
health
initi
gei
nih
support
research
lead
understand
genet
contribut
interact
common
diseas
nih
gei
award
million
grant
pacif
northwest
nation
laboratori
pnnl
hous
center
novel
biomark
respons
scientist
center
intend
creat
new
exposur
assess
tool
better
understand
role
interact
human
diseas
develop
tool
enabl
precis
measur
person
exposur
environment
chemic
biolog
agent
two
import
risk
factor
human
morbid
mortal
cigarett
smoke
obes
primari
target
interest
pnnl
scientist
research
focu
biomark
system
stress
caus
mainstream
secondhand
cigarett
smoke
obes
confound
physiolog
factor
research
compris
two
basic
element
genet
compon
reli
newfound
abil
swiftli
identifi
genet
differ
peopl
ill
healthi
lead
greater
understand
genet
contribut
diseas
environment
biolog
compon
focu
develop
new
technolog
accur
measur
person
exposur
small
wearabl
nanobiosensor
use
assess
environment
agent
center
provid
nih
nieh
databas
respons
biomark
well
chemic
substanc
select
biomark
test
valid
human
support
parallel
studi
mice
research
also
develop
nanobio
sensor
measur
biomark
poc
question
still
rais
whether
detect
diseas
earliest
stage
actual
improv
health
base
inform
present
variou
chapter
report
conclud
biomark
play
import
role
futur
medicin
biomark
consider
impact
diagnost
facilit
develop
person
medicin
role
biomark
manag
variou
diseas
also
discuss
biomark
alreadi
play
import
role
manag
cancer
screen
approach
led
dramat
chang
outcom
cervic
cancer
promis
area
futur
applic
biomark
diseas
diagnos
earliest
stage
hope
effect
intervent
new
class
sensit
imag
technolog
spiral
ct
made
specif
combin
biomark
blood
diseas
relaps
detect
earlier
entir
new
type
protein
biomark
one
area
discuss
far
role
biomark
prevent
medicin
health
educ
biomark
profil
healthi
individu
may
use
guid
individu
health
counsel
suscept
certain
diseas
may
requir
modif
gener
prevent
medicin
advic
futur
studi
need
establish
effect
approach
integr
rapid
semiport
prototyp
point
microbi
detectionidentif
system
propos
clinic
specimen
also
capabl
differenti
microbi
bioterror
attack
threat
hoax
defin
pathogen
white
et
al
system
util
flash
extractionanalyt
system
capabl
detectionidentif
microb
environment
clinic
matric
system
coupl
demonstr
technolog
provid
quantit
analysi
lipid
biomark
microb
includ
spore
system
nearsinglecel
amolmicrol
sensit
tandem
mass
spectrometri
increas
specif
provid
molecular
structur
neutral
lipid
phospholipid
derivat
sporespecif
bacteri
biomark
acid
well
lipopolysaccharideamidelink
hydroxyfatti
acid
gramneg
bacteria
extract
take
hour
sampl
multipl
sampl
process
simultan
malditof
msspecif
biomark
shown
effect
tool
identifi
microorgan
feasibl
techniqu
demonstr
detect
oblig
intracellular
bacterium
coxiella
burnetii
categori
b
bioterror
agent
shaw
et
al
establish
associ
environment
agent
diseas
present
challeng
epidemiologist
toxicologist
particularli
case
complex
interact
long
latenc
exposur
diseas
epidemiolog
valu
biomark
lie
abil
predict
backward
toward
exposur
forward
toward
risk
clinic
outcom
world
health
organ
recogn
biolog
marker
potenti
improv
way
exposur
environment
factor
assess
howev
valid
biolog
marker
avail
time
could
effect
use
epidemiolog
studi
assess
risk
need
new
approach
assess
dna
damag
increas
due
implic
differ
insult
genet
materi
may
human
health
context
identif
chemic
agent
differ
mechan
action
ie
antineoplast
drug
damag
dna
provid
good
model
investig
cellular
molecular
mechan
underli
basi
genet
toxicolog
nasal
epithelium
first
barrier
environment
pollut
interact
reason
epithelium
use
sentinel
order
assess
interact
environ
live
organ
take
phenomena
account
use
simpl
sensit
rapid
method
singlecel
gel
electrophoresi
could
obtain
inform
initi
approach
dna
statu
assay
combin
techniqu
provid
inform
molecular
paramet
could
give
us
better
view
biolog
statu
live
cell
identif
chemic
agent
differ
mechan
action
damag
dna
provid
good
model
investig
cellular
molecular
mechan
underli
genet
toxicolog
nasal
epithelium
first
barrier
environment
pollut
interact
use
assess
interact
environ
live
organ
possibl
assess
dna
statu
use
simpl
sensit
rapid
method
singlecel
gel
electrophoresi
mussaligalant
et
al
assay
combin
techniqu
provid
inform
molecular
biomark
could
provid
better
view
biolog
statu
live
cell
organophosphoru
op
compound
still
among
wide
use
insecticid
main
mechan
acut
toxic
associ
inhibit
acetylcholinesteras
measur
urin
metabolit
blood
cholinesteras
activ
establish
biomark
exposur
op
earli
biolog
effect
recent
year
increas
attent
given
biomark
suscept
op
toxic
polymorph
paraoxonas
liver
serum
enzym
hydrolyz
number
op
compound
play
role
modul
toxic
op
import
determin
statu
encompass
polymorph
affect
catalyt
abil
toward
differ
substrat
level
modul
part
polymorph
straight
genotyp
epidemiolog
studi
opexpos
worker
includ
assess
statu
valid
human
popul
role
determin
suscept
op
indic
anim
studi
need
document
exposur
earli
health
effect
would
relev
increas
predict
valu
test
mani
advanc
human
health
care
appli
anim
health
fact
new
technolog
test
experiment
anim
introduc
human
medicin
dog
suffer
mani
diseas
human
valu
measur
blood
level
myocardi
protein
cardiac
troponin
ctnl
test
diagnosi
congenit
acquir
heart
diseas
dog
evalu
sever
heart
failur
spratt
et
al
serum
sampl
obtain
healthi
dog
dog
diagnos
varieti
congenit
acquir
heart
condit
assay
ctnl
concentr
use
autom
immunoassay
method
result
also
analyz
accord
degre
heart
failur
assess
use
intern
small
anim
cardiac
health
council
scheme
healthi
dog
low
undetect
blood
ctnl
level
dog
congenit
heart
diseas
howev
ctnl
level
significantli
elev
dog
acquir
mitral
valv
diseas
dilat
cardiomyopathi
pericardi
effus
blood
ctnl
level
also
vari
sever
heart
failur
measur
blood
ctnl
level
may
use
aid
diagnosi
dog
suspect
heart
diseas
indic
sever
heart
failur
